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Tuberculosis (TB) is a preventable and a treatable disease yet it is considered to be one of the 
most common infections seen in HIV. People who are infected with HIV are 20 times more 
likely to develop TB than those without HIV.  Globally, there are nearly 40 million people living 
with HIV and at least one-third of them are infected with TB.  Ontario accounts for the highest 
number of TB cases in Canada yet HIV-TB co-infection in Ontario is not well described. Despite 
the close relationship between TB and HIV and increasing efforts to fight both concurrently, TB 
continues to create economic and social burden in HIV infections. 
 
Our study estimates the prevalence of active and latent TB and identifies risk factors associated 
with TB in a cohort of individuals living with HIV in Ontario. Cases diagnosed with HIV during 
2001 to 2009 were extracted from the Ontario HIV Treatment Network Cohort Study (OCS). 
Reviewing Mantoux test results, diagnoses and medication history, identified active and latent 
TB cases. Period prevalence was estimated by proportion with TB and multivariate analyses 
were performed to identify associated factors.  
 
One thousand two hundred and ninety-three cases (1293) met our selection criteria. Three 
hundred and eighty four (384; 29.7%) were 29 years or younger, 805 (62.3%) aged between 30 
years and 50 years and 104 (8.0%) aged 50 years or older. One thousand and nine (1009; 78.0%) 
were males. Four hundred and sixty six (466; 36.0%) had at least one record of a Mantoux skin 
test. The prevalence of active TB was 76/1293 = 0.0587 or 5.87% (95% CI 4.6% to 7.0%) 
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whereas the prevalence of latent TB varied from 5.26% (68/1293 = 0.0526) 95% (CI 4.0% - 
6.5%) to 11.37% (53/466 = 0.1137) 95% CI (8.2% to 13.7%) depending on the methodology.  
 
In the multivariate analysis, factors associated with active TB were age and birthplace. 
Individuals 50 years and older were more likely to have active TB than individuals 30 years and 
younger (OR 4.3 CI (1.7-12.7), p <0.01). Individuals born in Africa were more likely to have 
active TB than Canadian born (OR 14; 95% CI (5.9 – 32.8) p < 0.001). Factors associated with 
latent TB were sex and birthplace. Females were more likely to have latent TB than males (OR 
2.4; 95% CI (1.1 – 5.2) p < 0.05). Individuals born in Africa were more likely to have latent TB 
than Canadian born (OR 12.3; 95% CI (4.7 – 32.1) p < 0.001).  
 
TB remains a major problem in persons infected with HIV with rates disproportionally high 
among the foreign born population. Low rates of Mantoux tests in OCS present a missed 
opportunity for active TB prevention among individuals with HIV.  To identify individuals with 
higher risk of having TB after HIV diagnosis, better screening tools to identify latent TB are 
needed.  Consideration should be given to data capture systems that would ideally be linked 
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CHAPTER 1 OVERVIEW OF TB/HIV CO-INFECTION 
1.1 Overview 
Tuberculosis (TB) is a preventable and a treatable disease, yet it is the leading cause of death in 
people with HIV in most parts of the world, particularly in Africa (1). While the overall 
occurrence of TB is on the decline, there has been an increase in the number of reported cases of 
TB in people with HIV. This may be due to people with HIV having a weakened immune system 
(2). Ninety percent (90%) of people with HIV can die within a year of diagnosis of TB unless 
properly treated. In 2008, there were an estimated 1.4 million HIV positive TB patients, of which 
500,000 people died of HIV-associated TB in that same year (1). Globally, there are nearly 39 
million people living with HIV and at least one-third of them are infected with TB (2). The 
majority of HIV and TB co-infections occur in sub-Saharan Africa, where up to 80 percent of TB 
patients may be co-infected with HIV (2).  
 
In 2009 in Canada, the Public Health Agency of Canada (PHAC) reported 1600 new and 
relapsed cases of TB (3). While TB is on an overall decline in Canada, specific population 
groups continue to account for high number of cases reported (3). Foreign-born individuals and 
Canadian born Aboriginals accounted for nearly 63% and 21% of all the reported TB cases in 
2009, respectively (3). Ontario continued to have the most number of TB cases with 654 cases in 
2007 (4).  
 
HIV prevalence has been steadily increasing in Canada due to steady incidence rate and also 
because more Canadians are now living with HIV infection due to Highly Active Antiretroviral 
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Therapy (HAART). An estimated 65,000 Canadians were living with HIV at the end of 2008 (5). 
In terms of new cases, 2,300 to 4,300 HIV infections occurred in 2008 (5). The majority of the 
new HIV positive tests came from three provinces with Ontario having 42.7%, Quebec 24.7% 
and British Columbia 13.6% of all the cases (5).  
 
Many of the factors associated with increasing HIV prevalence such as poverty, social inequities, 
weak public physical and social infrastructures, are also core determinants of TB (6). Co-
infection with HIV and TB complicates patient management with potential complications of 
treatment and medication interactions (7). People with HIV have an increased risk of developing 
active TB whereas active TB can have a complex effect on HIV treatment (7).  
 
Although HAART has dramatically reduced mortality and AIDS related morbidity among HIV 
patients, TB remains a major opportunistic infection. Canadian Tuberculosis Standards 
recommended that all HIV-infected individuals should be screened for TB using tuberculin skin 
test (TST) (8). However, several studies have shown significantly low adherence to such 
recommendations (9-14). Results in a Swiss cohort study have underlined the need for 
improvements in TB screening among HIV-infected patients (15). To our knowledge, no studies 
have been conducted in Ontario to assess the adherence rates of TB screening in HIV-infected 
patients. Furthermore, 26% of all the HIV prevalent cases in Canada are not aware of their HIV 
infection (16), which puts them at a higher risk of developing active TB. As many individuals 





This study supports Canada’s role in the Global Plan to Stop TB, which aims to reduce the 
burden of the disease by 50 % compared to the mid 1990 levels (17). It also aims to eliminate TB 
as a public health problem by 2050.  The main objectives of the Global Plan to Stop TB are to 
achieve universal access to high-quality care for all people with TB and protect vulnerable 
populations from TB, TB/HIV and drug-resistant TB (18).   
 
We believe that this study will provide benefits to people living with HIV in Ontario as well as to 
the Ontario Cohort Study (OCS) participants, who are a vulnerable group at much higher risk of 
developing TB. Such benefits may include access to improved tools for TB screening, better 
linkages between Public Health and HIV clinics, vigilant monitoring for drug-resistant TB and 
finally prevention of TB occurrence in HIV infected persons. Results of this study will help 
researchers estimate the burden of HIV related TB in Ontario.  The results of this study will also 
help to engage communities and researchers in working together to generate the knowledge that 





CHAPTER 2 TUBERCULOSIS 
2.1 Historical Context 
Tuberculosis was once thought to be a disease of the past yet one-third of the world's population 
is infected with TB (19). Each year, an estimated eight million people worldwide develop active 
TB and two to three million die from it (20).  
 
The TB epidemic in Europe, later known as the “great White Plague” started at the beginning of 
the 17th century, and continued for the next 200 years (21). Death from TB was thought to be 
inevitable and TB was the leading cause of mortality by 1650. The necessary environment for the 
spread of this disease was provided by high population density and poor sanitary conditions in 
the enlarging cities of Europe and North America at that time (21). In the 1900s, general 
improvements in public health and the introduction of anti-tuberculosis drugs led to greater 
control of TB, but it never quite disappeared. Around 1985, TB cases started to rise again in 
industrialized countries. Several factors such as homelessness, injection drug use, crowded 
housing, immigration, and increase in prison populations drove the resurgence of TB. Above all, 
HIV further fuelled the re-emergence of TB. Also, TB program activities were less intense 
because the disease was regarded as close to elimination (21).  
 
In the early 1990s, the World Health Organization (WHO) started to prioritize activities to 
globally combat TB. The World Health Assembly of 2000 supported the establishment of a 
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Global partnership to stop TB and to reduce the global burden of TB by 50% by 2015 in relation 
to the 1990 levels (17). In spite of such global efforts, TB remains a threat, in part because of its 
synergistic relationship with the HIV pandemic (21).  
 
2.2 Epidemiology of Tuberculosis 
2.2.1 Global Burden 
Despite the known characteristics and treatment, TB still remains a major cause of morbidity and 
mortality worldwide, especially in Asia and Africa. Globally, TB has infected about one-third of 
the world's 5 billion people (22). The World Health Organization (WHO) has estimated that 9.27 
million new cases of TB occurred in 2007. The global prevalence of TB has been in decline since 
1990s. This decline can be explained by two factors: 1) a decrease in the average duration of 
disease as number of cases treated in the Directly Observed Treatment Short (DOTS) programs 
has increased and 2) a relatively short duration of TB mainly because of marked reduction in life 
expectancy among people with advanced HIV infection (23). Despite the overall decline in 
global prevalence, regions in Africa and Europe continued to have prevalence rates that were 
increasing during the 1990s (23). Furthermore, in terms of mortality, an estimated 1.77 million 
people died of TB in 2007. Of these 1.77 million, 1.32 million were HIV negative and 456,000 
were among HIV-positive people (24). Mortality attributable to TB in HIV infected people 





TB was a major cause of morbidity and mortality during the first half of the 20th century. 
Thereafter, rates declined rapidly as a result of improvements in the living conditions and public 
health measures to control disease transmission (8). Over the past two decades, reported TB 
cases have continued to decrease.  In 2006, members of a National Consensus Conference on 
Tuberculosis decided to set the Canadian goal to reduce the incidence rate of TB in Canada to 
3.6 per 100,000 by 2015 (8).  
 
 According to the PHAC TB report of 2009, 1600 new and relapsed TB cases (rate of 4.8 per 
100,000 population) were reported in 2008. The data suggests an increase of 1.5% from 1,577 
cases in 2007 to 1600 cases in 2008 (8). Individuals who were visitors or were born outside of 
Canada account for over two third of all reported TB cases in Canada (25). The Canadian 
tuberculosis committee and its Immigration subcommittee recommended that all immigrants to 
Canada undergo TB screening using chest radiography, which is mainly used to detect active TB 
and may miss opportunities to detect latent TB (25). People from countries where TB rates are 
high and in whom previous TB reactivation is likely, arrive in Canada each year with 250 000 as 
landed immigrants and another 2 million as visitors (22). Of the 250,000 immigrants and 
refugees coming to Canada each year, 80% of them originate from TB endemic countries (8).  
The proportions of TB cases that are foreign born persons have increased significantly, rising 
from 18% of all cases in 1970 to 67% in 2004 (8). In 2008, foreign born individuals accounted 
for 63% of all reported TB cases in Canada whereas Canadian-born non-Aboriginal accounted 




The Canadian Aboriginal population includes Status and non-Status Indians, Inuit and Metis. In 
2004, these groups together constituted 3.5% of the overall Canadian population but accounted 
for 17% of the TB burden (8).  While the TB cases in Aboriginal populations is generally higher 
than among Canadian born non-Aboriginal peoples, there is broad variation in the levels of 
disease among these communities and regions. For example, the status Indians have a TB 
incident rates ranging from 0 per 100,000 in Atlantic Regions to 72.7 per 100,000 in Manitoba 
(8). Similarly, the Inuit people have an incident rate of 95 per 100,000 in Quebec but 102.2 per 
100,000 in the Northern territories (Yukon, Nunavut, and Northwest Territories) (8).  
 
2.2.3 Ontario  
Ontario continues to have more TB cases than any of other Canadian provinces (4). One third of 
Canadian TB cases are in the Greater Toronto Area (GTA). The majority of Ontario cases are 
foreign-born individuals (4). In 2007, Ontario reported 654 new TB cases, a rate of 5.1 per 
100,000 (4). In Canada, drug-resistant 1TB is most commonly reported in foreign-born 
individuals. In Ontario, particularly in GTA, the rate of drug resistant TB is much higher than 
that of other regions of Canada (4). Furthermore, HIV epidemic has had a dramatic impact on TB 
rates and on TB control in populations where both infections are prevalent (26). 
 
                                                
1 Drug-resistance is further described in Section 2.9. 
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2.3 Cause of TB 
TB is caused by a bacillus called Mycobacterium tuberculosis. M.tuberculosis multiplies 
relatively slowly compared to most other bacteria. It is also a strictly aerobic bacterium and 
multiplies efficiently in pulmonary tissue where the oxygen concentration is high (27). Primary 
TB infection almost always occurs in the lung because of inhalation of droplets carrying the TB 
bacillus. Therefore, it usually infects the lungs (pulmonary TB or PTB) but can also occur in 
other parts of the body (extra-pulmonary TB) including the kidneys, spine and brain. Major 
symptoms of TB are cough, fever, weight loss and weakness (27).  
 
2.4 Transmission 
TB is transmitted from person to person by the airborne route (20). A person with active TB 
disease has the potential to infect a large number of individuals (4).  The source of infection is 
most often a person with cavitary pulmonary TB who expectorates bacilli by coughing or 
sneezing. During this process, the person produces tiny infectious droplets, which are then 
inhaled by another person in the vicinity (27). Infectivity of a person is related to the quantity of 
bacilli contained in his/her sputum. The most contagious person is the one with sputum smear-
positive microscopy (M+). Those with only culture-positive results (M-, C+) are less contagious 
and person whose sputum smear microscopy and culture are negative (M-, C-) is generally not 
contagious (25). Transmission normally requires close, frequent and prolonged exposure to a 
source case (27). In order to fully transmit the disease, certain factors must be met. These factors 
include 1) viable presence of bacilli in the sputum or larynx of the source case; 2) aerosolization 
of sputum by cough or other mechanisms; 3) adequate concentration of bacilli in the air; 4) a 




2.5 Latent TB 
The lung is the primary entrance point of the tuberculosis bacillus, which causes a localized 
infection in the lung (21). The infection spreads to local lymph nodes and through the blood 
stream to other body sites. The bacilli pathogens are taken up by macrophages at many sites in 
the body and may remain dormant for years. This is referred to as latent TB. Most TB disease in 
adults is reactivation of TB at one of these sites, most often the lung. Direct progression to active 
TB is more likely when infection occurs in young children (4). In most individuals, latent TB 
infection clinically results in no apparent symptoms and the infection may stay latent for life or 
until reactivation (4). The individual with latent TB is also not contagious. A weakened cellular 
immune system such as in those with HIV may allow multiplication of previously dormant 
bacilli and activation of the disease (4). The development of active TB disease will take place in 
5%-10% of latent TB infected persons at some point in their lives. Approximately 5% of persons 
who have been infected with TB will develop active TB disease within two years of exposure to 
the disease and the other 5% will develop active TB disease sometime later in their lifetime 
depending on the risk factors (21).  
 
2.5.1. Risk Factors for Latent TB 
Factors that increase the risk of acquiring latent TB infection (LTBI) in Canada involve 1) Close 
contacts of an infectious case of TB; 2) Immigrants and visitors from countries of high TB 
incidence; 3) Persons who are homeless; 4) Elderly persons who lived through an era when TB 
was common; 5) Aboriginal communities with high rates of LTBI or TB disease; 6) Healthcare 
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workers or persons at risk due to occupational exposure and 7) Residents of long-term care 
facilities and correctional facilities (4).    
 
2.6 Active TB 
For the 5-10% who will acquire active TB disease, development and further multiplication of 
bacilli will continue.  With active TB disease, the tubercle bacilli will replicate in the lungs, and 
due to the interaction of the bacillus and the cellular immune system, and area of tissue necrosis 
develops and hence a cavity. This active replication may result in more than 108 (10 to the power 
of eight) bacilli per cavity with a diameter of less than 2 cm (21). The development of tubercle 
cavities in the lung builds a platform for the infectious material to spread further through bronchi 
(21). The individual may start to have TB symptoms like coughing, chest pain, fever and 
weakness. At this point, the individual is contagious and can spread M.tuberculosis bacillus to 
other persons in the surroundings (21). 
 
The disease progression may be different in persons with HIV, depending on the status of their 
immune system. If the immune system is severely compromised, the classic cavity may not form, 
and although there may be large numbers of bacilli in the sputum, lack of a cavity may 




2.6.1. Risk Factors of active TB 
Factors that carry a high risk of developing active TB among persons with latent TB infection are 
1) Acquired immunodeficiency syndrome (AIDS) or HIV infection; 2) Organ transplantation- 
linked to immunosuppressant therapy; 3) Silicosis; 4) Chronic renal failure requiring 
hemodialysis; 5) TB infection within the past two years; 6) Abnormal chest X-ray and 7) 
Children less than 12 months of age (5). 
 
2.7 Diagnosis   
This section is further divided into two categories: 1) Diagnosis of Tuberculosis Infection and 2) 
Diagnosis of active Tuberculosis Disease. According to the Ontario’s TB Best Practices 
guidelines, a TB case is defined as an individual: 1) with positive culture of Mycobacterium 
tuberculosis from sputum, body fluids or tissues or 2) without bacteriological evidence but with 
clinical signs and symptoms, radiological or pathological evidence of active pulmonary or non-
pulmonary disease (28). The primary instrument to diagnose TB infection is the tuberculin skin 
test (TST) whereas diagnosing active tuberculosis disease usually consists of three aspects: a) 
symptoms, b) radiographic presentation and, c) evidence of mycobacterium (i.e. specimen 
collection for acid fast bacilli smear and culture) (28).  
 
2.7.1 Diagnosis of latent TB 
The tuberculin skin test (TST) is a useful method of diagnosing TB infection, however it is not as 
helpful in the diagnosis of active TB disease. Over the past few years, a significant advancement 
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has been the development of T-cell based interferon-gamma release assays (IGRAs), another test 
designed to identify individuals with LTBI (29).  
 
Tuberculin Skin Test (TST) 
Tuberculin Skin Test (TST) is comprised of the intradermal injection of a small amount of 
purified protein derived from Mycobacterium tuberculosis bacteria. In a person with cell 
mediated immunity to tuberculin antigens, a hypersensitivity reaction will occur within 48 to 72 
hours (30). 
 
In general, testing for latent TB is recommended when the risk of developing active TB disease 
is increased (8). There are many common situations when the risk of developing active disease is 
increased: 1) recent TB infection, most commonly contacts of a person with a recent diagnosis of 
active, contagious respiratory TB, 2) foreign born coming from countries of high TB incidence. 
3) increased risk of reactivation due to impaired immunity including HIV infection and other 
immunosuppressed conditions, diabetes, renal failure, immunosuppressant medication and 
pulmonary silicosis. 4) radiographic evidence of previous, healed inactive TB with no prior TB 
treatment (8).  
 
There is a possibility of false negative TST results, particularly in people with HIV. At least 20% 
of patients with active TB may have a negative TB skin test. A higher number of false negative 
results, close to 50% are observed in persons with HIV infection, depending on their immune 
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status (30). Therefore, a negative TB skin test never rules out TB whereas a positive skin test 
alone is not enough to establish the diagnosis of active TB (30).  
 
A positive skin test is defined by the size of the swelling. A skin reaction size of 0-4 mm in a 
person with a compromised immune system due to HIV infection and with a high likelihood of 
TB infection is usually considered positive (4). A skin reaction of 5-9 mm in a person with HIV 
infection, close contact of active contagious TB case, abnormal chest X-ray or other immune 
suppression is considered positive. All the other persons with a skin reaction size greater than 10 
mm are also considered positive (4). Other factors to evaluate with the TST results include non-
tuberculosis mycobacteria (NTM) and Bacille Calmette-Guerin (BCG) vaccination (4). 
 
 NTM are species of mycobacteria and may present as opportunistic infection in the immune 
compromised individuals. Common clinical symptoms linked with NTM are lymphadenopathy, 
chronic pulmonary disease and skin or soft tissue infections (4).  
 
The appropriate interpretation of TST result needs prior knowledge of the possible confounding 
factors such as previous Bacille Calmette Guerin (BCG) vaccination. Although many countries 
have stopped the usage of BCG vaccination, it is still offered in high TB prevalence populations 
and in high-risk groups such as newborn Canadian Aboriginals living on reserve (31). 
Immunization with BCG significantly increases the possibility of a positive TB skin test and 
therefore the interpretation of the skin test should be done in the individual clinical context and 
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evaluation of other risk factors for infection (31). BCG vaccination provides protective effect 
against TB. In a meta-analysis study on efficacy of BCG in the prevention of TB, the risk of TB 
was significantly reduced by 50% on average with the use of BCG vaccine (32). 
 
BCG vaccine is mainly used in TB control and prevention programs to prevent complications in 
undiagnosed TB persons who do not have access to early identification and treatment of TB (33).  
BCG is thought to reduce hematogenous spread of Mycobacterium tuberculosis from the site of 
primary infection (33). In Canada, BCG immunization programs exist in some First nations and 
Inuit communities, targeting newborns and individuals in certain high-risk settings (33). BCG 
vaccination is contraindicated for people with a compromised immune system or people with 
immune deficiency disease including HIV infection (33). A previous administration of BCG 
vaccine has the potential to make interference with surveillance efforts of investigating active TB 
cases (31). 
 
Interferon Gamma Release Assays (IGRAs) 
Until recently, the only diagnostic test available to diagnose latent TB was TST.  However, as 
previously mentioned, TST has its limitations since a false-positive result can occur among 
individuals with a BCG vaccination or who have been exposed to NTM. A false-negative result 
can occur in individuals with a compromised immune system (34). As a result, Interferon-
gamma release assays (IGRAs) were recently developed to address many of these limitations 
(34). IGRAs are whole blood tests that can help in diagnosing latent TB (29). IGRAs works on 
the principle that T cells of a person sensitised with tuberculosis antigens produce interferon 
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when they reencounter mycobacterial antigens. Therefore, a high level of interferon is indicative 
of latent TB (35). 
 
Previous systematic reviews (35-37) have shown that IGRAs have a higher specificity in low TB 
incidence settings however such reviews were not able to assess the diagnostic ability of IGRAs 
in HIV-infected persons. A recent study in 2011 performed a systematic review to determine 
whether IGRAs should replace TST as a screening tool for latent TB in HIV-infected persons. 
The study found insufficient evidence to conclude that either test was superior to the other (34). 
 
Two IGRAs that are currently approved in Canada are the QuantiFERON-TB Gold (QFT) assay 
and the T-SPOT.TB assay (29). The TST is still recommended to be the initial test used to detect 
latent TB, however due to a possibility of false negative TST result in an immune compromised 
person, a clinician concerned about the possibility of latent TB with a negative initial TST result 
may perform an IGRA test (29).  
 
2.7.2 Diagnosis of active TB Disease 
Symptom Presentation 
Depending on the duration and site of TB disease, the symptom presentation can be highly 
variable. The primary symptoms for pulmonary tuberculosis include chronic cough for three or 
more weeks, fever, and night sweats. When the TB disease gets to an advanced stage, other 
symptoms such as hemoptysis (coughing of blood), anorexia, weight loss and chest pain also 
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appear (4). The symptoms of extra-pulmonary TB are often site specific such as lymph node 
swelling, neurological changes (i.e. headache or neck stiffness), bone pain/joint swelling, lower 
back pain, urinary tract infections in renal TB disease, or abdominal pain or infertility. 
Pulmonary and Extra-pulmonary TB can occur at the same time (4).  
 
Radiographic Presentation 
Chest X-rays with both posterior-anterior and lateral views are mechanisms towards diagnosing 
pulmonary tuberculosis. A typical radiographic presentation of tuberculosis includes infiltrates, 
nodules, and cavities in the upper lobes of the lungs or superior segment of the lower lobes (4). 
Other abnormalities may include fibrosis, scarring, granulomas, or volume loss (due to 
destruction of lung tissue or lung contraction by the tuberculosis bacillus) (4). 
 
Mycobacterial Evidence 
Mycobacterium tuberculosis (MTB) is a slow growing mycobacterium, which usually takes up to 
seven weeks to grow in order to acquire a final culture result (4).  
 
 Acid Fast Bacilli (AFB) Smears 
Acid Fast Bacilli (AFB) is a laboratory rapid test used to analyze specimen for the presence of 
TB bacilli (20). The specimen is smeared onto a microscope slide, stained and then examined 
(4). If the TB bacilli are found in the specimen, it is referred as smear positive TB. It is graded 
according to the amount of bacilli per field with No AFB (negative), Few (weakly positive), 1+ 
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(moderately positive), 2+ (moderately positive), 3+ (strongly positive), 4+ (strongly positive). 
Although AFB smears test is rapid, specific for bacteria and with not many types of equipment 
needed, it is less sensitive than culture. It can detect only concentrations of at least 10-5 bacilli 
per ml of specimen. A single sputum smear has sensitivity between 22% and 80% (20) 
depending on the bacterial load. Therefore, multiple (usually three) sputum smears are used to 
increase sensitivity. The specificity of smear method also varies with different population 
groups. It is quite high in developing countries but much lower in developed countries due to the 
frequent presence of atypical mycobacteria (i.e. bacteria other than those causing TB) (20). Both 
mycobacterium tuberculosis and non-tuberculosis mycobacteria will result in AFB smear 
positive. It is important to determine whether a positive AFB smear is caused by MTB or NTM 
(4). 
 
 Mycobacterial Culture 
In Ontario, every specimen that is sent for AFB smear testing is also cultured for mycobacteria 
(4) at the Public Health central laboratory. The culture for M.tuberculosis is considered the gold 
standard of diagnosing TB. Cultures are usually associated with higher detection rates, because 
sensitivity is higher than that of AFB smears (20). Although six cultures are required to achieve 
100% sensitivity, three cultures are recommended in Canada because the sensitivity of three 
exceeds 90% and create a balance between high sensitivity and efficiency (30). Nevertheless, 
cultures occasionally can be false negative, mainly because of cross-contamination inside the 




2.8 TB Treatment 
Patients diagnosed with active disease of Tuberculosis take oral drug treatments for duration 
without even hospitalization unless it is a severe case or MDR-TB, and can easily return to their 
daily life routine (38). TB treatment is classified as first-line or second line drug treatments. 
First-line drugs are the drugs of choice administered to patients after their diagnosis of TB. These 
drugs are generally more effective, less toxic, cheaper and easier to administer than the second 
line agents. The most common first-line drugs are isoniazid (INH), rifampicin, streptomycin, 
ethambutol, and pyrazinamide (38). The primary purpose of TB treatment is to eliminate the 
infection in the body, prevent resistant strains and control transmission of the disease. If TB 
remains untreated, 50% of the cases with active TB disease would die within 2 years (20).  
 
2.9 Drug Resistant TB 
Drug resistant TB is a form of TB in which the bacteria have become resistant to the first-line TB 
medicines. Resistance to TB drugs occurs when these drugs are misused or mismanaged.   
Multidrug-resistant (MDR) TB is when TB bacteria are those that are resistant to the two most 
common TB medications, isoniazid and rifampin (39). The most dangerous form is Extensively 
Drug-Resistant (XDR) TB where the bacteria is resistant to many common TB medicines such 
as, isoniazid, rifampin, fluoroquinolone, and at least one of three injectable medicines 





CHAPTER 3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
3.1 Background 
The human immunodeficiency virus (HIV) is a virus that infects cells of the immune system, 
notably CD4 T cells (a type of white blood cell vital to fight off infections), destroying or 
impairing their functions (40). As the immune system becomes more damaged, the individual 
may develop severe opportunistic infections and cancers, resulting eventually to Acquired 
Immunodeficiency Syndrome (AIDS). According to WHO, the critical criteria used to diagnose 
the progression to AIDS is when any condition listed in the clinical stage IV of WHO’s clinical 
stages2 is diagnosed and/or the CD4 count is less than 200 cell/mm3 (40).  
 
3.2 Clinical Background 
Once the HIV enters the body, it is widely spread, mainly to lymphoid tissues (41). As time 
progresses, the quantity of HIV increases in the blood while the number of CD4 T cells decline 
(42). Antiretroviral Therapy (ART) is a potent combination of medications that inhibits viral 
replication and reduces the amount of virus present in the body, allowing CD4 T cells to increase 
in numbers, and improvement in function of the immune system (42). People who are HIV 
negative and generally are in good health have approximately 800 to 1200 CD4 T cells per cubic 
millimetre (mm3) of blood. However, with the HIV infection, the CD4 T count drops 
dramatically (42).  
 
                                                
2 WHO’s clinical stages are listed in Appendix A 
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3.2.1 Symptoms and Diagnosis 
Most people will experience very few, if any, symptoms in the early stages of HIV infection. 
Some individuals may have flu like symptoms including fever, headache, tiredness and enlarged 
lymph nodes in the neck and groin area (43). However, these symptoms usually disappear within 
a week to a month and are often mistaken for influenza or another viral infection (43). 
Individuals during this period are highly infectious as the amount of HIV present in the body is 
in large quantities. Symptoms vary from person to person and some may experience severe 
symptoms initially, while others may not experience any symptoms at all for 10 years or more 
(43). As HIV progresses to the late stages, the virus severely compromises the immune system 
and individuals may develop symptoms including 1) weight loss; 2) recurring fever or profuse 
night sweats; 3) extreme and unexplained fatigue; 4) prolonged swelling of the lymph glands in 
the axilla, groin or neck; 5) diarrhoea that lasts for more than a week; 6) sores of the mouth, anus 
or genitals; 7) pneumonia; 8) red, brown, pink or purplish blotches on or under the skin or inside 
the mouth, nose or eyelids and 9) memory loss, depression and other neurological disorders (43).  
 
3.3 Epidemiology of HIV 
HIV is a worldwide pandemic that has killed more than 25 million people to date (44). 
According to the WHO, nearly 33.4 million were living with HIV in 2008. During the same year, 
2.7 million people were newly infected and 2.0 million died of AIDS (45). Two thirds of HIV 
infections are found to be in sub-Saharan Africa (45).  
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3.3.1 HIV Prevalence in Canada 
The first reported case of HIV was reported in 1982 in Canada. Since then, it is estimated that a 
total of 65,000 people were living with HIV in Canada at the end of 2008, which is an increase 
of approximately 14% from the estimated 57,000 in 2005 (46). 
  
Due to advances in HIV treatment, many people are living longer with HIV infection, 
contributing to the rising prevalence of Canadians living with HIV (47). The majority of the 
reported HIV cases in 2008 came from three provinces: 42.7% from Ontario, 24.7% from 
Quebec and 13.6% from British Columbia (5). However, trends in the newly diagnosed cases 
differ among the provinces/territories with Saskatchewan having the highest rate (20.8%), twice 
those of Ontario (10.3%), while the lowest rates were reported in Newfoundland and Labrador 
(0.7%) and the territories (0.0%) (5).  
 
In terms of infection, men having sex with men (MSM) is the highest prevalence group with 
31,330 (48%) individuals, 11,180 (17%) Intravenous Drug Users (IDUs), 10,710 (17%) 
heterosexual/non-endemic, 9,250 (14%) heterosexual/endemic, 2,030 (3%) MSM-IDU and 500 
(1%) other exposures (46). The public health agency of Canada categorizes HIV exposure 
through a hierarchical system with Men having sex with men (MSM) being the highest in the 
hierarchy. For example, if a MSM from a HIV endemic country were HIV positive then he 




3.3.2 HIV Incidence in Canada3 
The number of newly diagnosed HIV cases in 2008 ranged from 2,300 to 4,300, which is around 
the same as the estimated range of 2,200 to 4,200 in 2005 (46). In terms of infection, MSM 
accounted for the highest proportion of new infections (44%) whereas the infections among 
IDUs increased to 350-750 (17%) in 2008 (46). Foreign-born Canadians and Immigrants from 
HIV endemic countries continue to be over represented in Canada’s HIV epidemic. 360 to 670 
(16%) of heterosexual/endemic cases were attributed in the new HIV infections in 2008. 
Individuals from HIV endemic countries account for 2.2% of the Canadian population but the 
estimated HIV incident rate among individuals from HIV-endemic countries is at least 8.5 times 
higher than among other Canadians (46). 
 
3.3.3 Undiagnosed HIV infections in Canada 
As mentioned earlier, an estimated total of 65,000 people were living with HIV by the end of 
2008 in Canada (46). Of this estimate, 16,900 (26%) of prevalent cases were unaware of their 
HIV infection (16). In terms of exposure category, the estimate percentage varies. It is estimated 
that 19% of MSM and 26% of IDU were unaware of their HIV infection while the heterosexual 
individuals who were unaware of their infection had a much greater proportion (35%) (16).  
 
3.4 Vulnerable Communities in Canada 
There are many different vulnerable populations living with HIV in Canada. Such populations 
include: 1) Gay, Bisexual and MSM; 2) people from HIV endemic countries; 3) Aboriginal 
                                                
3 Incidence implies new HIV infections within a specific time period. 
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People ; 4) Injection Drug Users ; 5) Mother to Child HIV Transmission vulnerability ; 6) Older 
Canadians and 7) Youth in Canada (48). The following information is the latest set of data 
available and as current as up to 2008 in most cases, except for the section of HIV endemic 
countries where the data is updated up to 2005.  
 
3.4.1 HIV among Youth in Canada 
Youth in Canada between the ages of 15 and 29 years have accounted for 26.5% of all positive 
HIV test reports since the beginning of HIV reporting (49). Canadian Youth in general are 
vulnerable to HIV infection due to many factors. Such factors include risky sexual behaviour, 
substance use that includes injection drug use, and lack of accurate information and awareness 
on HIV transmission (49). In terms of gender, males accounted for around 95.8% of the HIV test 
reports when reporting began in 1985. In 2008, proportion of females in the age group of 15-29 
was reported to be highest among all female HIV test reports and represented 33.5% of all 
positive HIV test reports among youth (49). Data from various studies show that street-involved 
youth, youth who are injection drug users, and youth men who have sex with men are at a higher 
risk of having HIV infection (50-53).  
  
3.4.2 HIV among Women in Canada 
According to the PHAC report in 2012, the proportion of HIV infection that represents women 
has been increasing over the last 10 years. In 2008, women accounted for 17% of people living 
with HIV and 26% of all new HIV infections in Canada (54). Also in the same year, three 
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quarters of newly diagnosed cases occurring among women are attributed to heterosexual sex 
exposure and more than one third can be attributed to exposure through injection drug use (54).  
 
There are certain groups of women who are more likely to be over-represented and 
disproportionately affected in the HIV endemic. Such groups are Aboriginal women, women 
from countries where HIV is endemic, injection drug users, and women in prison. For example, 
women from HIV endemic countries represent more than half of the positive HIV tests attributed 
to women (54).  
 
While biological differences in women increase their susceptibility to HIV than men, many 
factors, known as social determinants of health, also have an impact on women’s vulnerability to 
HIV (54). Factors such as gender, income, education, unemployment, access to stable housing, 
access to health services, social support services, racism, and early childhood development are 
social determinants will have an impact on women’s vulnerability to HIV (55-58). There are also 
other factors such as sexual violence, culture, HIV/AIDS related stigma, and discrimination that 
can make women more vulnerable to HIV (59-61).  
 
3.4.3 HIV among Older Canadians 
HIV and AIDS has generally been perceived as a disease that mainly occurs in younger people 
however, it is quite clear that older4 Canadians are not only affected but are also at risk of 
                                                
4 Older Canadians were defined as 50 years of age and older.  
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acquiring HIV infection (62). It is possible that older Canadians could have acquired the HIV 
virus after the age of 50 years or could have acquired it at a younger age and survived it into an 
older age, particularly due to the advances of highly active retroviral therapy (HAART) (62). 
9.6% of the cases that have been reported positive for HIV test since the beginning of HIV 
reporting up to 1985 accounted for older Canadians aged 50 years and above. 84% of this 
proportion was male and 48% of them were MSM (62).  
 
3.4.4 Perinatal HIV Transmission 
PHAC estimates that 25% of untreated HIV pregnant women will transmit the virus to their 
infant either during pregnancy or at birth (63). The percentage can further increase to 35% if the 
mother decides to breastfeed her baby. Overall, the situation of perinatal HIV transmission in 
Canada has significantly improved over the last decade (63).  Although the number of infants 
perinatally exposed to HIV has increased as there are now more people living with HIV, the 
number of these infants who were subsequently infected with HIV has had a dramatic decline 
(63). In 2001, out of the 168 infants born to HIV infected women, 10.01% were infected whereas 
in 2008, only 1.7% infants out of the 238 exposed to HIV were confirmed as infected. Highly 
active anti-retroviral therapy has played a major role in the decrease of HIV infected infants (63).  
 
3.4.5 HIV among Aboriginal People in Canada 
Aboriginal people represent 3.8% of the Canadian population yet they continue to be over 
represented in the HIV epidemic in Canada (64). It is estimated that in 2008, there were 4,300 to 
6,100 Aboriginal people who were living with HIV, which is 8.0% of the HIV prevalent 
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infections (64). In terms of new infections, there were 300 to 520 new HIV infections that 
occurred in Aboriginal population in 2008 only (64). According to the PHAC HIV related 
surveillance report (64), injection drug users (IDUs) in the Aboriginal population account for 
66% of the new infections, a rate much higher than among all other Canadians (17%). Aboriginal 
communities are disproportionately affected by many conditions termed social determinants of 
health such as, poverty, substance/drug use, and limited access to health care services. All these 
factors increase their vulnerability to HIV infection (65-67). 
 
3.4.6 HIV among Gay, Bisexual and Other Men Who Have Sex with Men in Canada 
The HIV epidemic continues to have a disproportionate effect on gay, bisexual and other men 
who have sex with men (MSM). This population accounts for the largest proportion of positive 
HIV tests among adults, representing 56.1% of total HIV positive test reports since the 
introduction of HIV reporting in 1985 (68).  MSM also accounts for the largest proportion of 
cases with a representation of 48% (31,330) of all the estimated prevalence in 2008 (68). Further, 
MSM continues to account for the largest proportion of estimated incident cases with an 
estimated proportion of 45% in 2008 (68). According to PHAC, recent data suggests that certain 
subgroups within MSM continue to be at high risk of HIV infection by engaging in unprotected 
sex with serodiscordant5 partners or partners of unknown HIV status (68).  
 
                                                
5 A term used to describe in which one partner is HIV positive and the other is HIV negative. 
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3.4.7 HIV among people who inject drugs in Canada 
Injection drug users constitute 17.7% of cumulative positive HIV reported cases up to 2008 (69). 
While there has been a decreasing trend noted in positive HIV cases attributable to injection drug 
use among men, an increasing trend has been observed among women since 2003. Of the 
proportion, for which age and exposure category was provided, the highest proportion among the 
injection drug use was accounted by individuals aged 30 to 30 years (33.5%) and 40 to 49 years 
(32.3%) (69). In the national estimates for 2008, IDU represented 17% (11,180) of all the 
prevalent cases where as the proportion for incident cases was estimated to be 17% (390-750) as 
well (69). It is further estimated that roughly 25% of this proportion (prevalent cases) were 
unaware of their infection. It was also observed that Aboriginal people represented 66% of the 
newly diagnosed cases in 2008 (69).  
 
3.4.8 People from Countries where HIV is Endemic 
The term “people from countries where HIV is endemic” refers to population that is mainly 
comprised of Black people of African and Caribbean descent (70). Although a number of Black 
Canadians are able to trace their roots in Canada all the way to the early 1600s and 1700s, this 
group largely came to Canada through immigration during the last five decades (70). 
 
According to the estimates by PHAC in 2012, people from HIV endemic countries represent 
14% of people living in Canada while they only represent 2.2% of the population (71). HIV 
endemic has a significant impact on women who come from HIV endemic counties. Females 15 
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years of age or older accounted for 55.3% of HIV positive test reports between 1998 and 2009 
and also represented 40.7% of AIDS cases during the same time period (70).  
 
Of the total prevalence of HIV cases in Canada (65,000 at the end of 2008), an estimated 9,250 
(14%) were people infected through heterosexual contact and were born in an HIV-endemic 
country (71). People from HIV endemic countries were also over-represented among new HIV 
infections. The estimated new infection rate among individuals born in HIV-endemic countries is 
approximately 8.5 times higher than among other Canadians (71).  
 
Many factors such as those described in social determinants of health have been observed to 
increase the Black population’s vulnerability to HIV. Such factors include income, education, 
unemployment, housing, early childhood development (e.g. history of child abuse), physical and 
social environments, access to health services, racism, support networks, gender inequalities and 
sexual violence (72-74).  
 
3.5 Smoking, HIV and TB 
While the rates of opportunistic infections such as TB, in individuals with HIV, have declined 
due to HAART medications, studies have shown that smokers are more likely to acquire 
opportunistic infections than non-smokers (75). While many previous studies related to smoking 
and TB have not considered the role of HIV infection in the past (75). Some studies also show 
that individuals with HIV are more likely to smoke than those without HIV. Individuals with 
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HIV who smoke cigarettes also have shown to develop AIDS faster than non-smokers (75).  
Smoking cigarettes and tobacco affect individuals with HIV in several ways. Smoking cigarette 
in individuals with latent TB also increases the risk of development of active TB by two to three 
times, compared to non-smokers (76). 
 
 
3.6 HIV Testing and Treatment 
Routine HIV testing is recommended for adults, adolescents, and pregnant women during routine 
medical care (77). HIV testing is performed by testing a blood sample to detect the presence of 
HIV specific antibodies (77). Since 1985, blood tests for HIV antibodies have been available in 
Canada. Standard HIV testing includes pre-test counselling. In the laboratory if the screening test 
is positive, the laboratory continues to do a confirmatory test called Western blot to rule out a 
false-positive result before sending the result back (77). The results are returned to the clinic 
after two weeks and the patient receives a post-test counselling (77). 
 
It is estimated that at least 26% of HIV-positive people are unaware of their HIV status (16). 
Therefore, it is imperative to improve access and ease of HIV testing across Canada. Many 
community based organizations and health service providers are increasingly using rapid point of 
care (POC) HIV testing, which may help to increase testing rates in the communities (77). This 
type of testing allows health service providers to deliver immediate HIV test results (77). In 
comparison with the standard HIV antibody test, during the use of POC test, patients are 
provided with pre-test counselling, and informed of the need for confirmatory blood work if the 
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POC test is reactive (77). The test itself is performed on a drop of blood from the finger, in a 
separate room out of the sight of the patient and the result is available within approximately two 
minutes (77). The individual is provided with post- testing counselling right after the test results 
are examined and again when they return to receive their confirmatory results one to two weeks 
later (77).  
 
There are many benefits associated with the use of POC HIV testing. It is much more portable 
than the standard HIV antibody blood test, which allows it to be performed in any kind of 
community settings (77). It also provides a better counselling experience since pre and initial 
post-test counselling is provided by the same person, which is often not possible to ensure with 
the two – week waiting period during the standard HIV testing (77)  
 
At present, there is no cure for HIV infection, however, there is HAART treatment available for 
HIV patients that can suppress the HIV viral replication and the progression of HIV infection. 
HAART consists of three or more anti-HIV drugs (78). Use of a single drug results in selection 
of resistance mutations. However, the chances of HIV mutation or replication are low if the 




CHAPTER 4 COINFECTION OF HIV AND TB 
4.1 Epidemiology of HIV/TB co-infection 
4.1.1 Globally 
Globally, there are nearly 39 million people living with HIV and at least one-third of them are 
infected with TB (2). People who are infected with HIV are 20 times more likely to develop TB 
than those without HIV (79). Ninety percent of people with HIV can die within months of 
contracting TB unless properly treated.  In people with HIV and latent TB, the chance of 
developing active TB increases by 6 times in the first year after HIV infection, and continues to 
increase over the years (22). In the absence of antiretroviral therapy, the likelihood of 
progressing to AIDS increases by 100 times when people with HIV develop active TB (80-81). 
In 2008, there were an estimated 1.4 million HIV positive TB patients, out of which 500,000 
people died of HIV-associated TB in the same year (82). The majority of HIV and TB co-
infections occur in sub-Saharan Africa, where up to 80 percent of TB patients may be co-infected 
with HIV (83).  
 
4.1.2 Canada 
While there is no national surveillance system that tracks TB and HIV co-infection rates, several 
Canadian studies have been conducted to determine the overlap of TB and HIV or even TB and 
AIDS. These studies mainly determined the burden of HIV among the TB population, 
particularly HIV testing in this population (83). However, not many examined the TB rates in 




A study by Geduld and Archibald (2005) reported 5.6% TB cases among all the AIDS cases 
reported to PHAC from 1994 to 2003 (84). Two thirds of TB and AIDS infected cases were 
foreign born. The study concluded that at least one in twenty AIDS cases were also infected with 
TB and a large proportion of these cases are among foreign born population (84).  
 
In a study of HIV related TB in British Columbia, Blenkush et al. (1996) found that there were 
44 people identified with HIV infection and TB during the period of 1990 and 1994 (85).  
Although the study identified the number of individuals rather than estimating the TB rate, the 
general over-lap of HIV and TB related cases in British Columbia was 3.8% (85). The mean age 
was 38 years among 37 men and 7 women. 70% of the participants were Canadian born and 18% 
came from countries where TB was highly prevalent.  52% (22/40) were Intravenous users and 
31% (14/44) were Aboriginal Canadians. The study also compared these proportions with the 
proportions of patients diagnosed with TB and HIV during the years of 1984 to 1990. The study 
concluded that there were significantly more intravenous drug users, Aboriginal Canadians and 
women with HIV-related TB than in the previous years of 1984 to 1990 in British Columbia 
(85).  
 
In a Quebec study on HIV related TB, Brassard and Remis (1999) reported 4,684 people with 
HIV, of which 5.2% had active TB at some point during their course of illness (86). The majority 
of people co-infected with HIV and TB were male (75.2%) and manual workers (40.1%). 
Montreal had the highest TB rate of 9.6% among those with HIV, possibly due to its urban 
setting (86). People with HIV who were born in an HIV-endemic countries in the Caribbean and 
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sub-Saharan Africa were 21.8 and 17.9 times more likely to have TB respectively than those 
born in Canada. Manual workers and unemployed people with HIV were 1.6 and 2.0 times more 
likely to have TB than professional workers with HIV. HIV was concluded to be a significant 
factor in the contribution of TB cases (86).  
 
A recent study conducted by Brassard et al. (2009) explored the proportion of TB screening 
among the HIV-infected patients (87). Out of the 2121 HIV patients observed in a Canadian 
clinic in a tertiary setting, 22.4% patients were treated by TST within 90 days of first clinic visit 
(87). 17 patients developed active TB, of which 9 (53%) had no documented TST prior to the 
diagnosis of TB. The study found inconsistencies in the administration of TSTs to newly 
diagnosed HIV patients and recommended that all patients should be screened for TB at the time 
of HIV diagnosis (87). 
 
A retrospective cohort study by Creatore et al. (2005) studied patterns of TB risk over time 
among recent immigrants to Ontario (88). 92% of TB cases in Toronto were accounted for 
people born outside of Canada (88). Although this study examined all the immigrants rather than 
only HIV positive population, conclusions made in this study were coherent with the study by 
Brassard et al. People from sub-Saharan Africa had the highest TB incidence, with a 96 times 
more risk than of the non-Aboriginal Canadian population (88). Overall, recent immigrants had a 
risk 23 times higher than non-Aboriginal Canadians. Region of birth, particularly countries 
where TB is highly endemic was a significantly higher risk of getting TB in people born outside 




4.2 Pathology, Clinical Picture and Diagnosis of HIV/TB Co-infection 
Individuals with HIV are vulnerable to reactivation of TB due to their weakened immune 
systems (89). CD4 T cells play a vital role providing protection from reactivation of 
M.tuberculosis (90). HIV infection is a major known risk factor for reactivation of LTBI-HIV 
infection. As the HIV infection progresses, the count of CD4 cell count declines. Therefore, the 
risk of active TB disease significantly increases as the HIV infection progresses and 
concentration of CD4 cells decline in count and function (91). A research study has estimated 
that the incidence of TB increases by a factor of 2.1 for each reduction of 200/ul in the CD4 
count (91). Although TB is an easily treated opportunistic infection taking place in HIV positive 
people, its clinical picture is often atypical which in many cases can lead to a delay in diagnosis. 
Latent and active TB can occur at any CD4 count. The nature and clinical features of TB 
depends on the immunosupression related to HIV (91).  
 
In HIV patients with early diagnosis of TB and a normal count of CD4 cells, the clinical 
symptoms (cough, fever and weight loss) are similar to that in HIV negative patients (91). As the 
level of immunosuppression increases, the clinical symptoms start to become non-specific and 
atypical. One of the challenges is that the fever and weight loss (classic symptoms of TB) can be 
common symptoms of HIV disease alone (91). A significant association has been explored 




Furthermore, the immunosuppression also has a negative impact on the sputum smear 
microscopy and TB culture as it reduces the sensitivity of such diagnostic tests. As the 
immunosuppression increases, the results of sputum smear and culture are often negative in late 
HIV disease (91). Similarly, the radiological findings are also different for HIV-positive person. 
The classical common changes associated with pulmonary TB are upper lobe infiltration, 
cavitation and fibrosis, but as HIV disease progresses, diffuse shadowing and miliary infiltrates 
are more common radiological findings (91). 
 
Tuberculin skin testing (TST) also has its limitations when it comes to testing for TB in people 
with HIV. The sensitivity of this test is significantly reduced in HIV-positive people, particularly 
those with advanced HIV disease (92). Individuals with AIDS may not show a positive skin test 
result despite TB infection or disease. (92). 
 
4.3 Prevention and Treatment of TB in people with HIV 
Treatment for latent TB also called TB prophylaxis is used to prevent active TB diseases. It is 
suggested to health care providers that they consider treatment for individuals with a positive TB 
skin test and where the presence of active TB has been ruled out (4). Isoniazid (INH) is one of 
the medications used to treat latent TB since its first effectiveness was reported in 1957. As the 
drug has been proven to be safe, cheap and easy to take, its effectiveness depends on adherence 
to treatment with adequate duration. Patients who took 80% or more of the recommended doses 




In HIV positive individuals, the Lung Association of Canada suggests that prophylaxis treatment 
for latent TB should be offered regardless of TB skin test. The recommended dosage of INH for 
latent TB in adults is 5 mg/kg/day (max.300 mg daily) (4).  However, compliance remains a 
significant barrier to an effective prophylaxis. In various settings, compliance rates were only 
50% to 75% through one year of preventive therapy (93).  In one study involving Canadian 
Aboriginals, a program of daily-observed prophylaxis and education improved compliance rates 
but were not sustained after the observation was discontinued (94). 
 
Despite the close relationships between the two diseases (TB and HIV) and increasing efforts to 
fight both concurrently, uptake of policies linking HIV and TB has been slow (83). As many 
individuals with HIV are not tested for TB, the prevalence of HIV-TB co-infection is not well 
described. Further, adults with TB infection have about a 10 % chance of developing TB disease 
in their lifetime while those co-infected with HIV have a 10 % risk of developing TB disease 







5.0 ONTARIO HIV TREATMENT NETWORK (OHTN) 
The datasets were provided by Ontario HIV Treatment Network (OHTN), which is an 
independently incorporated, not-for-profit organization funded by the AIDS Bureau and Ontario 
Ministry of Health and Long-Term Care (96). OHTN works towards better HIV treatment, 
research, and education in Ontario. It is a collaborative network of researchers, health service 
providers, policy makers, community members, volunteers and people with HIV (96). The 
OHTN owns and houses a clinical and epidemiological database on people with HIV in the 
province. This database is called OHTN Cohort Study (OCS). It has been used as the basis of 
data analysis for the thesis study. OCS has its roots in AIDS activism and the demands for 
research that would improve the quality of life of people living with HIV (97). OCS is unique in 
comparison with other HIV cohorts because it is community driven and involves all the 
stakeholders including people living with HIV, dedicated HIV care physicians, researchers and 










6.0 RESEARCH OBJECTIVES 
 
The overall objective of this study is to estimate the prevalence of TB in the OCS database and to 
identify risk factors associated with TB among people living with HIV. The specific research 
objectives are as follows: 
 
1.) To determine the period prevalence of active and latent cases of TB among HIV positive 
individuals in the OCS database during the period of January 2001 to Dec 2009.  
 
2.) To identify risk factors associated with active TB in the OCS database. 
 
3.) To identify risk factors associated with latent TB in the OCS database. 
 





CHAPTER 7.0 METHODOLOGY 
7.1 Study Design 
Our study of TB will be based on observational data that is already collected and currently stored 
in OCS database. Our group of interest was participants diagnosed with HIV during the period of 
January 2001 to Dec 2009. This time period was selected so it would provide rich demographic 
and clinical data on most recent HIV diagnosis since the OCS has undergone changes in adding 
social and psychological data in addition to the clinical data. .  
 
7.1.1 Inclusion Criteria 
1) Participants in OCS diagnosed with HIV during the time period January 2001 to Dec 
2009. 
 
7.1.1 Ethics and Data Confidentiality 
This study was approved by the Research Ethics Board (REB) of University of Ontario Institute 
of Technology (UOIT). The OCS data are governed by the REB of University of Toronto. A data 
confidentiality agreement was signed between OHTN and the researchers (see Appendix D).  
 
7.1.2 OCS Database 
The source of data is OHTN’s Cohort Study (OCS) database. OCS is a multi site research study 
that collects clinical and socio-behavioural information voluntarily from people with HIV across 
Ontario (98).  There were eleven HIV sites across Ontario that provided data to OHTN on 
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regular intervals (98). Five of the sites were located in the GTA, and one site was located in 
Sudbury, Ottawa, Kingston, Windsor, and London. Other sites in Ottawa and Hamilton were not 
actively recruiting participants as of date (98).  Once a person is diagnosed with HIV, sites may 
wait up to a year before they approach HIV positive individuals to participate in the OCS. 
Individuals who were diagnosed with HIV prior to the site opening were immediately recruited 
after the site opening (98). Participation in the study is voluntary and patients are assured that the 
provision of treatment and clinical services will continue at the same standards regardless of their 
participation in the OCS. They can refuse to participate in the study or withdraw from the study 
at any time. Participants must be consented before participating (98). 
 
Personal data such as name, address, health care number, etc., is used at the recruiting site to 
generate a complex encrypted unique identifier, which allows the person’s data to be accurately 
tracked at OHTN while keeping it confidential. The process is strictly anonymous and one-way 
encryption cannot be decrypted to reveal the original information that was used to create the 
unique identifier (99).  No personal identifier information is stored in the database. The HIV 
clinics mainly use a computer-based systems or chart abstraction tools to collect clinical data 
(100). Data is loaded onto the OHTN database using secure methods. For sites using chart 
abstraction, an electronic data abstraction tool is used to collect clinical data elements (100). 
OHTN provides funding to HIV clinics so that they can hire qualified staff to perform chart 




Access to the data in the OCS database is approved by the OCS Governance committee who can 
allow specific subsets of the data to be accessed by researchers according to the purpose of the 
study (101). The committee is governed by people living with HIV as well as other stakeholders 
in the HIV community to ensure that it’s intended use is appropriate and meets community’s 
ethical requirements (101).  
 
OCS is the only HIV cohort study in Ontario that collects a combination of different data 
elements for each individual. It is unique in a way that it gathers socio-behavioural information 
as well clinical information. OCS collects social behavioural information through an annual in 
person interview (101). The social behavioural questionnaire includes data elements such as 
demographics, employment, substance use, smoking, immigration, mental health, housing, 
stigma, stress, social support, medication and adherence (101). Data retrieved from clinical 
charts include, diagnosis, medications, adverse events, medical charts, viral load and CD4 count 
and other medical tests (101). Additional data including viral load and genotypic test is obtained 
from Public Health Laboratories (PHL) (101). 
 
After the recruitment process, data for each individual is collected retrospectively (i.e. clinical 
history, infection date) as well as prospectively (i.e. annual interviews and ongoing clinical data 




There are over 5,600 participants who have enrolled in the OCS. It is a diverse group of people 
living with HIV in Ontario. Although, most OCS participants are MSM (Men having sex with 
Men), a significant number are also females or individuals infected by a different mode of 
transmission (98). The average age at enrolment is 41 years and over one third of participants 
reported a race other than white (98). As of 2010, 63% of the participants enrolled in the study 
were still actively participating. The remaining participants were lost to follow up either because 
they were deceased (14.6%) or were recruited in sites that are no longer collecting data (3.2%) 
(98).  
 
A quick snapshot of the OCS data sample in 2008 provides some characteristics of OCS 
participants (n = 1,406). The mean age of the participants is 47 (SD 10.0) with 85% of them 
being male. 70% of the participants are either gay, lesbians, or bisexual and 73% of them are 
white (101). In terms of other demographic factors, 85% of them have more than high school 
education and 44% of them were employed. The proportion of participants earning a personal 
income greater than $30,000 a year was 44% (101). From a clinical perspective, 47% of the 
participants have had their recent CD4 count to be greater than 500 cells/ml and 74% of the 
participants have had their recent viral load to be undetectable. 21% of the participants present in 
the OCS database had an AIDS-defining condition whereas the mean years since HIV diagnosis 



























 HIV diagnosis during Jan 
2001 to May 2009 
Exclusion Criteria 
 HIV diagnosis outside of 
2001 to 2009 
 
OCS Datasets required for the included 
participants 
Tests Diagnosis Medications Participant 
Demographics 
Data Elements 
CD4, Viral Load and 
TB Skin test 
- Lab test code 
- Type of Test 
- Date/time 
- Test Result 








- Stop date 
- Indication as HIV 
related 
- Indication as pre-
existing 
- Method of diagnosis 
- Type of diagnosis 
- Status (ongoing, etc) 
Data Elements 
TB Medications  
(INH,RMP,PZA,EMB) 




- Indication for use 
- Nature of indication 
(prophylaxis vs. 
treatment) 
- Date Stated 
- Date Stopped 
- Reason for 
discontinuation 







- Region of Birth and 
Immigration Status 
- Education Level 
- Ethnic origin, race 
- Gender 
- Employment Status 
- Household income 
- Occupation 
- Province of residence 








7.2 Data Request to OHTN 
A formal proposal was drafted for the OCS review committee, requesting the data needed in 
order to achieve the study’s research objectives (see Appendix E). The figure in the previous 
page includes a detailed list of data elements required from the OHTN to proceed with this study.  
The list of variables that were required included sex, age, race/ethnicity, HIV transmission risk, 
smoking status, rural/urban residence, recency of HIV infection, recency of immigration, TB 
skin test record, CD4 count, Viral load count, co-morbid conditions, TB and HIV treatment and 
duration and dates of death if applicable.  
 
7.2.1. Datasets provided by OHTN 
Upon approval by the OCS committee, data was provided on an encrypted USB drive. The 
research laptop that was used was also protected using the encryption software (True Crypt). All 
participants matching the inclusion criteria were part of the data analysis. Individuals who 
withdrew from the study due to loss of follow up or due to death were still included in the 
sample, as they had previously provided demographic and clinical data to OCS.  
 
The data consisted of nine datasets and was provided in both SAS and SPSS versions. Most of 
the data analysis was performed using SPSS version 19. The nine datasets included were: 1) 
demographics, 2) TB mantoux records, 3) TB diagnosis, 4) adverse events, 5) AIDS Defining 





The dataset was originally named "main" and it contained 1293 unique records with 17 variables 
that were associated with demographic characteristics of these individuals. The variables were 
organized in the following order: cohort IDs (cohort_id) date of HIV diagnosis 
(min_hivposdate), Gender (sex), region of birth (countryrgn), HIV risk transmission 
category(hivriskcat), Area of residence (urban_rural), Mortality (death), Age at the time of HIV 
diagnosis (hivpostestage2), year of death if the person is not alive (deathyear), participants for 
which the death year is unknown (deathyear_unknown), date of interview with the OCS staff 
(interviewdt), History of Smoking (cigaretteHistory), smoking frequency (perWeekDay & 
howMany), age at the start of smoking (age), smoking duration in years (Years) and how long 
have they been living in Canada if they were foreign born Canadians (yearsinCanada). 
 
Mantoux Skin Test Dataset 
The dataset was named “tb_mantoux” and it contained 732 records and 9 variables. The 
variables were in the following order: Cohort IDs of participants (cohort_id), grouping of type of 
test (group 1), subgrouping (sub_group1), name of the OCS test (OCS_TEST_NAME), date of 
the lab test, result (Result_Value), details of the result (TEST_RESULT_DETAILS) and 
description of the test (TEST_DESC).  Of the 732 records, 172 (23.5%) had more than one 





The dataset was named “tb_dx” and it contained 11 records and 4 variables. The variables were 
in the following order : Cohort IDs (cohort_id), diagnosis description (dxdescription), date of the 
diagnosis (DXDATE), and diagnosis date flag (DXDATE_FLAG).  
 
Adverse Events Dataset 
The dataset was named “tb_ae” and it contained 26 unique records and 5 variables. The variables 
were in the following order: Cohort IDs (cohort_id), result of the adverse event 
(RESULT_VALUE), description of the event (test_desc), lab test date (labtestdate), and lab test 
date flag (labtestdate_flag).  
 
AIDS Defining Condition (ADC) Dataset 
The dataset was named “tb_adc” and it contained 30 unique records and 4 variables. The 
variables were in the following order: Cohort IDs (cohort_id), description of the diagnosis 
(dxdescription), date of the diagnosis (DXDATE), and diagnosis date flag (DXDATEFLAG).  
 
TB Medications Dataset 
The dataset was named “tb_meds” and it contained 149 records and 12 variables. The variables 
were cohort IDs (cohort_id), treatment and prophlyaxis (T_VS_P), ATC Code (ATC_Code), first 
stop reason (stop_reason_1), second stop reason (stop_reason_2), third stop reason 
(stop_reason_3), generic drug name (generic_name), brand drug name (brand_name), medication 
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start date (medstartdate), start date flag (medstartdate_flag), stop date (medstopdate), stop date 
flag (medstopdate_flag). 149 records belonged to 75 unique cohort IDs as each unique ID had 
more than one TB medication listed in the medication history.    
 
Antiretroviral Medication Dataset 
The dataset was named “arv” and it contained 5694 records and 13 variables. The variables were 
cohort IDs (cohort_id), generic drug name (generic_name), brand drug name (brand_name), drug 
class (drug_class), ATC coding (ATC_code), start date of medications (medstartdate), start date 
flag (medstartdate_flag), drug dosage (dose), drug dosage unit (unit), frequency of prescribed 
drug (frequency), method of intake (route), stop date (medstopdate), stop date flag 
(medstopdate_flag). 5,694 records were of the 1033 unique cohort IDs as each unique ID was on 
several different medications.  
 
CD4 count Dataset 
The dataset was named “cd4” and it contained 19065 records and 11 variables. The variables 
were cohort IDs (cohort_id), CD4 Test Date (CD4TestDate), CD4 Test Date Flag 
(CD4TestDate_Flag), CD4 Numeric Result-Standard (RESULT_NUMERIC), CD4 Character 
Result Standard (RESULT_CHAR), Laboratory Result Qualifier (lab_qual), Flag for converted 
CD4 results (result_flag), Units - Standard International (result_unit), First CD4 Test Date Flag 
(fcd4date_flag), Last CD4 Test Date Flag (lcd4date_flag) and minimum CD4 Result Test Date 
Flag (mcd4date_flag). 19,065 records were of the 1237 unique cohort IDs as each unique ID had 




Viral Load Dataset 
The dataset was named “vl” and 1284 individuals had 22,227 records and 7 variables. They 
variables were cohort IDs (cohort_id), Viral Load test date (vltestdate), Undetectable Viral Load 
(undetectable), Viral Load (vl), Viral Load test date flag (vltestdate_flag), first Viral Load test 
flag (fvldate_flag), and last Viral Load test flag (lvldate_lag).  
 
7.3 Data Manipulation and Descriptive Statistics 
Demographic Variables 
An initial frequency analysis of all the datasets was performed to examine any missing values 
and to ensure it was coded appropriately.  In the demographics dataset, the age variable 
(hivpostestage2) contained ages of participants at the time of their HIV diagnosis. This variable 
was provided in a continuous variable format.  Two new categorical variables were created so 
the data can be categorized in different age groups. Other HIV-TB related studies were followed 
as a guide to organize the data. Initially, only one age categorical variable 
(ageatHIVdiagnosis_var4) was created which categorized the data into five different age group 
(years): 15 to 19, 20 to 24, 25 to 44, 45 to 64 and 65 and above.  However, another age variable 
(ageatHIVdiagnosis_var1) with only three different age groups was created so there is less 
variation in the regression analysis. This variable categorized the data in the age groups (years) 
of: 29 and less, between 30 and 49, and 50 and above. Frequency results of both variables were 




The birthplace data (countryrgn) originally provided were grouped into thirteen different 
birthplace regions. To create broader categories and to minimize the risk of identifying OCS 
participants, several regions were grouped together. A new variable for birthplace regions 
(countryregion_var2) was created and regions of Middle East, South Asia, Europe, Pacific 
Ocean, Atlantic Ocean, Russia, Central and South America, which had cell frequencies less than 
five, were merged according to geographical relevance. Asia and Pacific Ocean were merged 
into a new category called Asia and Pacific regions. Europe, Atlantic Ocean and Russian 
Republic were merged into a new category called Europe and Central Asia. South America and 
Central America were merged into another new category called South and Central America.  
Aboriginal Canadians were excluded from the Canadian category and were placed into a new 
category due to clinical relevance (Health inequalities in Aboriginal’s Canadians). In order to 
identify Canadian and foreign born individuals, a new demographic variable 
(CdnbornvsForeignborn) was created to categorize the participants either into Canadian born or 
foreign born based on their birth region. While a new variable (birth_region) was created and 
several birthplace groups were further merged together to reduce variations in the analysis. 
Caribbean was merged with South and Central America. Africa, Aboriginals and Canada were 
left as is whereas all the remaining categories were merged into “Others”.   
 
Frequency analysis was performed to describe the characteristics of the data. Variables related to 
enrolment in OCS used in the frequency analysis were 1) Follow up Status, 2) Follow-up 
duration, 3) Duration between HIV diagnosis and OCS enrolment. Follow-up status variable was 
already provided in the demographic dataset. Follow-up duration was measured by subtracting 
the HIV diagnosis year from the last interview year of each individual. The values were grouped 
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in three categories of < 12 months, 12-24 months, and > 24 months.  Duration between HIV 
diagnosis and OCS enrolment was measured by subtracting the HIV diagnosis date from the 
OCS enrolment date. The values were grouped in four categories of < 1 year, 1-2 year, 2-5 years 
and > 5 years. The frequency and the percentage of each category of the variables were 
described.  If an individual was missing data for a required variable, that individual was censored 




CD4 cells are white blood cells that maintain the function of the human immune system. As the 
presence of HIV increases in the blood, the number of CD4 cells decline (36). For purposes of 
the study, the CD4 count nearest to the time of enrolment as well as nearest to the time of 
person’s HIV diagnosis was selected from the CD4 dataset. In order to identify the CD4 test 
nearest to the time of enrolment, a calculation in SPSS was performed which calculated the 
period differences between the time of enrolment and the time of CD4 test. SPSS computed the 
differences in seconds, which were converted into days by dividing by 86,400 (24x 60 x 60) and 
then dividing it again by 30, or 365.25 to get duration in months or years. The difference with the 
lowest monthly duration was selected as the CD4 test at the time of enrolment. Similarly, CD4 
test at HIV diagnosis was measured by subtracting the CD4 test dates from the HIV diagnosis 
dates. The CD4 count measured the CD4 cells per millilitre. Other HIV-related studies were used 




Viral load test measures the amount of HIV virus in the blood.  The average viral load count at 
the time of enrolment as well as at the time of HIV diagnosis was selected from the viral load 
dataset. In order to identify the viral load test nearest to the time of enrolment, a similar 
computation like the one described earlier for CD4 test, was performed in SPSS.  The 
computation calculated the period differences between the time of enrolment and the time of 
viral load tests. The difference was calculated in seconds by SPSS, which was further divided by 
86,400 to convert into days and then further by 30 or 365.25 to convert into months or years. The 
difference with the lowest monthly duration was selected as the viral load test at the time of 
enrolment. Once the viral load test at the time of enrolment and at the time of diagnosis was 
selected, the log was taken to display the results in the form of log 10 copies per milliliter. Other 
HIV-related studies were used as a model to classify the viral load count (log copies/ml).  
 
The year of HIV diagnosis for each participant was provided in the demographic dataset. Years 
were clustered in three different periods to see if the proportion of HIV diagnosis was consistent 
throughout the years. The three different calendar time period groups were 1) 2001 – 2003, 2) 
2004-2006 and 3) 2007 – 2009.  
 
7.4 Identifying latent TB cases 
Mantoux test records were extracted from the Mantoux dataset. Mantoux test records were 
collected retrospectively as well as prospectively for the participant as part of the OCS.  Mantoux 
test record was not available for everyone. Result values for each participant were coded as 




To identify the proportion of participants diagnosed with latent TB, Mantoux test records, TB 
medications and diagnosis datasets were examined. Participants who were coded “positive” for 
Mantoux test were deemed positive for latent TB.  For those participants with multiple Mantoux 
test records, the most recent test was selected. Participants who were on TB medications for the 
latent TB treatment were also deemed positive for latent TB. Participants with ‘negative’ or 
‘missing’ Mantoux test value were coded as positive if they were on treatment for latent TB. 
Other datasets of adverse events, Aids Defining Conditions and diagnosis were also searched to 
identify if there were any latent TB cases there. If any of these datasets indicated a participant 
with “positive for Mantoux test” or “latent TB”, then they were added into the positive category.  
 
7.5 Identifying active TB cases 
Active TB cases were identified from datasets of Diagnosis, Adverse events, AIDS defining 
conditions and TB medications. Participants with active TB were already coded positive in the 
datasets. TB medication dataset indicated whether TB medications were prescribed for treatment 
or prophylactic reasons.  Cases receiving medication for the treatment of TB were coded positive 
for active TB whereas cases receiving medication for TB prophylaxis were coded positive for 
latent TB.  
 
7.5.1 MDR-TB Cases 
The identification of drug resistant cases, particularly MDR-TB cases was based on the TB 
medications and the length of TB treatment for each case. MDR-TB cases were defined as cases 
65 
 
that were at least resistant to Isoniazid (INH) as well as Rifampin (RMP). Cases that were 
resistant to other combinations of anti-TB medications but not to INH and RMP were not 
selected as MDR-TB cases.  
 
In order to calculate the length of treatment for each person, a new variable was created that 
computed a subtraction between the start and the stop date of TB medications. The result values 
were calculated in seconds by SPSS and which were further divided by 86,400, and then 30 to 
convert the values from seconds days and months respectively. Another variable was created that 
categorized these values in four different durations; 1) Less than 6 months, 6 months to 12 
months, 12 months to 18 months, and 18 months and above. These categories were created based 
on the fact that the minimum length of treatment for a MDR-TB case is between 18 months to 24 
months. Next step was to select the cases that were on TB medications for at least 18 months. 
After identifying such cases, the anti-TB medications were checked to see whether or not they 
received INH and RMP. Cases that were on treatment for at least 18 months, received alternative 
anti-TB drugs instead of INH and RMP were categorized as MDR-TB cases.  
 
It is possible for someone with HIV who is enrolled in the OCS study to be previously infected 
and diagnosed with active TB. Analysis was performed to identify the proportion of active TB 
cases that were diagnosed before or after their HIV diagnosis. After the active TB cases were 
identified, they were further categorized in terms of the period in which they were diagnosed 
with active TB. The start date of the TB treatment or the date of the diagnosis was used as an 
indicator of their diagnosis. This date was stored in a ‘TB diagnosis date’ variable and was 
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subtracted from the HIV diagnosis date variable. An SPSS computation was performed that 
produced the output values in seconds which were further divided by 86,400 and then 365.25 to 
convert into days and years respectively.   
 
Proportions of cases with TB and without TB were entered in tables displaying results for 
bivariate and multivariate analysis. Particular attention was paid to any table columns with a 
frequency cell of zero or less than 5. Cells with a frequency of 5 or less had the categories 
collapsed in an appropriate way to eliminate those cells. 
 
7.6 Estimating active and latent TB prevalence 
Period prevalence of active TB was calculated by dividing the number of persons infected with 
active TB by the number of persons examined in the sample. For example, in a study where 6000 
individuals completed the questionnaire (or were examined) and of these 6000 people, 200 
suffered with a condition A, the prevalence of condition A in the cohort will be 200/6000 = 
0.033. Prevalence of active TB was expressed as a percentage, calculated by multiplying the 
ratio by 100.  
 
Similarly, period prevalence of latent TB was also calculated by dividing the number of persons 
infected with latent TB by the number of individuals in the cohort. The denominator was chosen 
to be all persons examined in the sample because latent TB cases were identified from more than 
one source. If we identified latent cases by only examining the Mantoux test records, then the 
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denominator would simply be the number of Mantoux test records. Latent cases were also 
identified via medication history (medication history data was captured of the whole sample) and 
the diagnosis data (also extracted from the entire dataset). By expanding our sources of 
identifying latent cases, the risk exposure is not just limited to cases with Mantoux test records, 
but the entire data sample.  This method assumes that a missing would be negative for TB.  
 
Another method was also performed in which, latent TB prevalence was estimated by taking the 
positive Mantoux test records and dividing them by the total number of Mantoux test records 
found in the OCS. Results that estimated the prevalence of latent TB were shown using both 
methods.  
 
7.7 Data Merging 
Once the data manipulation was processed, key variables from all the datasets were combined 
and merged into one dataset named “main_mantoux_adc_ae”. The common variable across all 
the datasets was “cohort_id” which was used to merge the variables. The key variables from the 
demographic dataset were cohort IDs, sex, age, birthplace, area of residence, HIV transmission 
risk factor, recency in Canada, smoking status, date of HIV diagnosis, interview date, and 
follow-up status. Variables such as diagnosis and diagnosis date from “diagnosis”, “adverse 
events” and “AIDS defining conditions” datasets were also merged. Drug name, medication start 
date and medication stop date from TB medication dataset were also merged. Clinical variables 




7.8 Bivariate and multivariate Analysis 
The risk factors that were associated with active TB and HIV in the OCS were identified using 
bivariate and multivariate analysis. HIV infected persons in OCS who had active TB based on 
clinical diagnosis and medication history were compared with HIV infected persons who did not 
have active TB.  Since reoccurrence of TB is a possibility even after the treatment of TB, cases 
that developed TB prior to their HIV diagnosis were also included.  
 
Based on the objectives of this study, the outcome variables were active TB, latent TB and 
Mantoux test record in OCS with a dichotomous outcome. For example, active TB had an 
outcome of 1 = with TB and 0 = without TB. Bivariate and multivariate analyses were performed 
to identify factors associated with the outcome variables. Demographic and clinical variables 
provided in the OCS datasets were selected to be included in the analysis. Several previous 
studies (84-88) were used as a guide to identify variables as risk factors associated with outcome 
variables. The independent variables or the covariates were age, sex, birthplace, HIV 
transmission risk factors, area of residence, smoking status, follow-up duration in the OCS, and 
the results for viral load and CD4 count at the time of HIV diagnosis and at the time of 
enrolment in OCS. All the variables were coded as categorical. For continuous covariates such as 
age, the values were categorized into different age groups.   
 
Bivariate analysis was performed by comparing the outcome variables with the rest of the 
individuals in the sample. Pearson Chi Square test was used to identify any level of association. 
The Odds Ratio (OR), is defined as the ratio of the odds for x = 1to the odds for x = 0, and is 
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given by the following equation where π is the probability of having TB given x = 1. Unadjusted 
Odds Ratios (OR), 95% Confidence Intervals (CI) were computed using bivariate logistic 
regression analysis. 
𝑂𝑅 =   
𝜋(0)/[1− 𝜋 0 ]
𝜋(1)/[1− 𝜋 1 ] 
Multivariate logistic regression analysis for each outcome variable was performed to adjust for 
any confounding factors in the covariates. The significance of each variable was measured using 
a Wald Statistic with chi-square distribution. Upon finishing the bivariate analysis, an 
independent variable with a p-value < 0.25 was a candidate for the multivariate model along with 
other variables known for clinical importance (i.e. gender and age).  The recommendation of 
choosing 0.25 level as a criterion for variable selection is based on the literature work of Mickey 
and Greenland (1989) on logistic regression, found in the book by Hosmer and Lemeshow (75). 
Their algorithm, in effect, retains candidate variables for which the bivariate test statistic 
(equivalent to a chi-square value) ≥ 1.32. Use of an alpha level higher than 0.25 has a 
disadvantage of including variables that are of questionable importance, whereas use of an alpha 
level lower than 0.25 may not include variables that were weakly associated in bivariate analysis 
but become important predictors of dependent outcome when taken together with all other 
variables. Area of Residency, CD4 count both at diagnosis and enrolment, and viral load both at 
diagnosis and enrolment were excluded since they did not show a significant association in the 
bivariate analysis as the p-value was greater than 0.25. Since the cumulative risk of TB depended 
on the duration of follow-up, this variable was also adjusted for by including it in the 
multivariate model. The final covariates included in the multivariate models were sex, age, 




Once the models representing the main effects were refined, the next step was to check for 
interactions among the variables in the model. However, the final decision whether the 
interaction effect should be included in a model were decided based on practical as well as 
statistical considerations as per the recommendations of Hosmer and Lemeshow (102). 
Computing the arithmetic product of variables that may have significant association created 
interaction variables. Comparing the standard errors and confidence intervals to bivariate models 
assessed collinearity in multivariate models.   If there was evidence of highly inflated standard 
errors and confidence intervals in the multivariate model, then suspected collinear variables were 
compared using chi-squared tests during our analysis.  Multivariate models with and without 
collinear covariates were also compared.  
 
Adjusted Odds Ratios (OR) and 95% CI were computed as part of the multivariate regression 
analysis. For each covariate, a reference group was used to compare the Odds Ratio proportions 
within each subcategory. For example, Canadian born category was the reference group for the 
birthplace variable. Values for Odds Ratios, 95% Confidence Intervals and p-values of each 




CHAPTER 8 RESULTS 
8.1 Descriptive Statistics 
Our group of interest had 1293 individuals in the cohort that matched the inclusion criteria of 
being diagnosed with HIV during the period of January 2001 to Dec 2009. One hundred and 
ninety nine 199 (15.4%) of the 1293 in the cohort were enrolled in OCS within a year of HIV 
diagnosis, 194 (15.0%) were enrolled between 1 to 2 years after HIV diagnosis, 479 (37.0%) 
between 2 to 5 years and 421 (32.6%) were enrolled after 5 years of HIV diagnosis. Figure 8.1a 
shows a graphical representation of time interval between HIV diagnosis and enrolment to OCS.  
Duration between HIV diagnosis and OCS Enrolment 
 
Figure 8.1a – Time duration between HIV diagnosis and enrolment in OCS. 1 = Less than 1 Year, 2= 1 Year and Less than 2 
Years, 3 = 2 Years and Less than 5 Years, 4 = More than 5 Years 
Of 1293, 1225 (94.7%) cases that had information on follow up duration in the database, of 
whom 422 (34.4%) were followed up for less than 12 months, 646 (52.7%) were followed up for 
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12 to 24 months and 157 (12.1%) were followed up for more than 24 months. Figure 8.1b shows 
a graphical representation of the follow-up of participants in the study.  
Follow-up of participants in the study 
  
Figure 8.1b – Duration of follow up in OCS (n = 1225) 
 
Demographic Characteristics6 
The majority of the individuals were males 1009 (78.0%) and 274 (21.2%) females. The 
remaining 10 (0.8%) had no information about gender in the database.  The mean age of the 
group was 36.5 (SD 10.0) years at the time of their diagnosis with HIV. The youngest person in 
the cohort diagnosed with HIV was 15 years old whereas the oldest person diagnosed with HIV 
was 81 years old.  384 (29.7%) were aged less than 30, 805 (62.3%) were aged between 30 and 
50, and 104 (8.0%) were aged 50 and above at the time of their HIV diagnosis. 
                                                




536 (41.5%) of the individuals were diagnosed with HIV during the years 2001 and 2003, 463 
(35.8%) were diagnosed during 2004 and 2006 and 294 (22.7%) were diagnosed between 2007 
and 2009. A graph illustrating this data is shown in Figure 8.1c whereas a graph illustrating HIV 
diagnosis per year is shown in Figure 8.1d.  
 
HIV cases diagnosed per 3 years 
 







HIV cases diagnosed per year (2001 – 2009) 
 
 
Figure 8.1d – Number of cases diagnosed with HIV per year. Columns represent year and rows represent number of cases 
 
639 (49.4%) of the 1293 individuals were non-Aboriginals born in Canada, 110 (8.5%) were 
Canadian born Aboriginals, 168 (13.0%) were born in Africa, 65 (5.0%) in Caribbean, and 61 
(4.7%) were born in Europe and Central Asia. A complete proportion of birthplace regions can 
be found in table 8.1. 
 
Of the 396 individuals who were recent to Canada, 294 (74.2%) had been living in Canada for 
more than 5 years whereas 102 (25.7%) have been living in Canada for less than 5 years. In 
terms of residency for the entire group, 1086 (84.0%) resided in an urban area where as 50 




In terms of HIV risk exposure category, men having sex with men (MSM) were most frequently 
represented with 684 (52.9%) individuals, 202 (15.6%) were in the people from HIV-endemic 
countries category, 149 (11.5%) were in the heterosexual category and 94 (7.3%) were in the 
Intravenous Drug Users (IDUs) category.  
 
Clinical Characteristics 
466 (36.0%) had at least one record of Mantoux skin test result in the database whereas (827; 
64.0%) had no record of any Mantoux test result. Medication history indicated 75 people to be 
on TB treatment medications, out of which 56 (74.7%) received medication for the treatment of 
active TB and 17 (22.7%) received medication for treating latent TB. 1033 (79.9%) of all cases 
were on HAART medications and 260 (20.1%) did not have a record of HAART medications in 










	  Baseline	  Characteristics	  of	  individuals	  matching	  the	  inclusion	  criteria	  
	  	  
Baseline	  Characteristics	  (n)	   Sample	  
n=	  1293	  
Percent	   Frequency	  
(%)	   (n)	  
Gender	  	   Male	   78	   1009	  
Female	   21.2	   274	  
Missing	   0.8	   10	  
Age	  Category	  1	   <	  30	   29.7	   384	  
30	  -­‐	  50	   62.3	   805	  
>50	   8.0	   104	  
Age	  Category	  2	   15-­‐19	   2.6	   34	  
20-­‐24	   8.9	   115	  
25-­‐44	   68.7	   888	  
45-­‐64	   19.3	   249	  
65	  and	  above	   0.5	   7	  
Canadian	  or	  Foreign	  Born	   Canadian	  Born	   57.9	   749	  
Foreign	  Born	   34.4	   445	  
Missing	   7.7	   99	  
Birthplace	  Region	  	   Canada	  (non-­‐Aboriginals)	   49.4	   639	  
Canada	  (Aboriginal)	   8.5	   110	  
Africa	   13	   168	  
Caribbean	   5	   65	  
Middle	  East	   0.8	   10	  
South	  Asia	   0.6	   8	  
Asia	  or	  Pacific	  Regions	   3.6	   47	  
Europe	  or	  Central	  Asia	   4.7	   61	  
North	  America	  (excluding	  Canada)	   2.9	   37	  
Central	  and	  South	  America	   3.8	   49	  
Missing	   7.7	   99	  
Years	  in	  Canada7-­‐	  	  (n	  =	  396)	  	   <	  5	  Years	   25.8	   102	  
5-­‐10	  Years	   24.5	   97	  
>	  10	  Years	   49.7	   197	  
	   Continued... 	   	  
	   	   	   	  
                                                
7 This category is for those who reported to be born outside of Canada 
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Baseline	  Characteristics	  of	  individuals	  matching	  the	  inclusion	  criteria	  (cont’d..)	  
	  	  
	  	  
Baseline	  Characteristics	  (n	  )	   Entire	  Cohort	  
n=	  1293	  
Percent	   Frequency	  
(%)	   (n)	  
HIV	  Risk	  Categories	   MSM	   52.9	   684	  
-­‐1293	   HIV-­‐	  endemic	   15.6	   202	  
	  	   Heterosexual	   11.5	   149	  
	  	   IDU	   7.3	   94	  
	  	   MSM-­‐	  IDU	  both	   4.4	   57	  
	  	   Clotting	  Factor/Transfusion	   1.2	   15	  
	  	   Others/NIR	   7.1	   92	  
Living	  Area	   Urban	   84	   1086	  
Rural	   3.9	   50	  
Missing	   12.1	   157	  
Clinical	   Baseline	  Mean	  CD4	  count	  (cells/mL)	   0-­‐1440*	   376.9**	  





Mantoux	  Test	  Record	   Yes	   36.0	   466	  
No	   64.0	   827	  
Follow	  up	  Duration	   <12	  months	   32.6	   422	  
(in	  OCS	  Study)	   >	  12	  months	   62.1	   803	  
Smoking	  Status	  
	  	  
Never	  Smoked	   34.6	   448	  
Currently	  Smoke	   33.8	   437	  
Former	  Smoker	   16.2	   209	  
Missing	   15.4	   199	  
Year	  of	  HIV	  Diagnosis	  
	  	  
2001	  –	  2003	   41.5	   536	  
2004	  –	  2006	   35.8	   463	  
2007	  -­‐	  2009	   22.7	   294	  
Table 8.1 Baseline Characteristics of Individuals diagnosed with HIV from 2001 to 2009 
*indicates a range between the lowest and the highest value, rather than a percentage.  




Clinical data showed the mean CD4 count at the time of registration to the OCS study was 376.9 
cells/ml. 466 (36.0%) of the cohort had a CD4 count greater than 500 cells/ml, 632 (48.9%) had 
a CD4 count between 200 to 500 cells/ml and 139 (10.8%) had a CD4 count less than 200. There 
were 56 (4.3%) individuals who did not have a record of CD4 count at the time of registration. In 
terms of viral load, the baseline viral load count at the time of registration was 2.64 log10 copies 
per ml.  
 
1094 (84.6%) individuals had data on smoking status in the database, 448 (34.6%) of them never 
smoked, 437 (33.8%) currently smoke, and 209 (16.2%) were former smokers.  
 
In terms of interview dates of participants in OCS, 1098 (84.9%) of the 1293 cases had a record 







8.2 Prevalence of active TB in the cohort 
Of the 1293 individuals in the cohort, 76 had active TB. The period prevalence of active TB in 
the individuals diagnosed with HIV during 2001 to 2009 was 76/1293 = 0.0587 or 5.87% (95% 
CI 4.6% to 7.0%). Sixty-six (66) of 76 cases had the TB diagnosis date in the database. 52 
(78.8%) of the cases were diagnosed with TB after their diagnosis of HIV and 14 (21.2%) were 
diagnosed with TB before their HIV diagnosis. The occurrence of active TB relative to the time 
of HIV diagnosis is presented in Figure 8.2b.   When examined for a Mantoux test record in 
cases that were identified as having active TB, 37 (48.7%) of 76 TB cases had no record of a 
previous Mantoux test in the database.  
 
There were 30 active TB cases present in AIDS defining conditions (ADC) dataset, out of which 
9 were identified as pulmonary and 11 as extra-pulmonary. The other 10 cases were only labelled 
as active TB cases.  In the adverse event dataset, 7 were identified as active TB cases.  When 
medication history data was explored, 56 cases received treatment for active TB. 17 out of the 56 
cases were excluded as they were already identified in adverse events and ADC. The remaining 
39 were added to the list of active TB cases. Based on the treatment regimen and duration of 
treatment, there were no MDR-TB cases identified in the database.  A complete flow chart of TB 
cases is presented in Figure 8.2.a. 
 
To examine an association between active TB and a previous negative Mantoux test, cross tab 
analysis between the two variables was performed. There were 4 (10.0%) cases that had a 
previous negative Mantoux test result but were identified as active TB cases in the database.   
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Flow Chart to identify TB Cases 
 
 
Figure 8.2a –Active and Latent TB cases in the datasets provided. Mantoux tests, adverse events, AIDS defining conditions, 




Time duration between HIV Diagnosis and active TB 
 
Figure 8.2b – Time interval between HIV diagnosis and active TB diagnosis. The interval labelled HIV diagnosis (0) represents 
patients diagnosed with tuberculosis at the time of HIV diagnosis. 
 
73 of 76 active TB cases were still actively participating in OCS. Two (2) were lost to follow up 
and one (1) person died. In terms of the duration of the follow-up, 70 of 76 cases had a record of 
last follow up date, out of which 57 (81.4%) were followed up for more than 12 months whereas 






TB Diagnosis at a fixed interval 
 
Figure 8.2c – Diagnosis of active TB at a fixed interval.  
 
8.2.1 Characteristics of cases with active TB 
Of the 76 cases diagnosed with TB, 40 (52.6%) were males and 35 (46.1%) were females. 20 
(26.3%) were aged 29 years and less, 38 (63.2%) were aged between the years of 30 and 50, and 
8 (10.5%) were aged 50 and 81  
 
53 (69.7%) of these individuals were foreign-born Canadians whereas 13 (17.1%) were born in 
Canada, out of which 2 were aboriginal Canadians. Of the 53 foreign-born Canadians, 39 
(51.3%) were African and 6 (7.9%) were born in Caribbean or Latin America. A detailed list of 




48 individuals with active TB who were born outside of Canada provided data on how long they 
have lived in Canada. 19 (25.0%) of these individuals had lived in Canada for less than 5 years 
and 29 (60.4%) had lived in Canada for more than 5 years.   
 
In terms of HIV exposure category, 39 (51.3%) individuals with TB were from HIV-endemic 
countries, 11 (14.5%) were MSM, and 4 (5.3%) were IDUs. 59 (77.6%) individuals with active 
TB were living in urban areas in Ontario and 3 (3.9%) were living in rural Ontario.  
 
72 out of 76 TB cases had data on CD4 count at the time of registration. 26 (34.2%) had a CD4 
count more than 500 cells/ml, 40 (52.6%) between 200 and 500 cells/ml, and 6 (7.9%) had a 











Characteristics of individuals with active TB and HIV 
 Frequency (n) Percent (%) 
Gender Male 40 52.6 
Female 35 46.1 
Missing - 1.3 
   
Age < 30 20 26.3 
30 – 50 48 63.2 
> 50 8 10.5 
   
Birthplace Region Canada (non-Aboriginals) 11 14.4 
Canada (Aboriginal) - 2.6 
Africa 39 51.3 
Caribbean - 5.3 
South Asia - 1.3 
Asia and Pacific Regions 4 5.3 
North America (excluding Canada) - 3.9 
Central and South America - 2.6 
Missing 10 13.2 
   
Follow up Duration < 12 months 13 7.1 
12 – 24 months 45 59.2 
>24 months 12 15.8 
Missing 6 7.9 
   
HIV Risk MSM 11 14.5 
HIV-endemic 39 51.3 
Heterosexual 8 10.5 
IDU - 6.6 
Others 13 17.1 
   
Smoking Status Never 38 50.0 
Former 8 10.5 
Smoke 15 19.7 
Missing - 5.3 
 
Table 8.2 Characteristics of individuals with active TB and HIV 





8.3 Prevalence of latent TB in the cohort 
Of the 1293 cases examined, 68 had latent TB. The period prevalence of latent TB cases in 
individuals diagnosed with HIV during 2001 to 2009 was 5.26% (68/1293 = 0.0526) 95% (CI 
4.0% - 6.5%). 50 of the 68 cases (73.5%) were followed up for more than 12 months, 13 (19.1%) 
were followed up for less than 12 months and 5 (7.4%) had no data on the duration of follow-up.  
 
The prevalence of latent TB is estimated to be much higher if only Mantoux test records are used 
as per the other method described on page 68. Of the 466 Mantoux test records with a definite 
result, 53 were positive. Therefore, the period prevalence of latent TB according to this method 
was to 11.37% (53/466 = 0.1137) 95% CI (8.2% to 13.7%)  
 
8.3.1 Characteristics of latent TB cases 
Of the 68 latent TB cases, 35 (51.5%) were females, 32 (47.1%) were males and 1 (1.5%) did not 
provide information on gender.  Distribution of gender proportion between HIV only and 
HIV/Latent TB groups is provided in Figure 8.3a.  
 
22 (32.4%) individuals were aged 29 years and less, 39 (57.4%) aged between 30 and 49 years 











Distribution of Gender Proportion between HIV only  
and HIV/Latent TB groups 
 
Figure 8.3a – Gender proportions distribution for Latent TB/HIV and HIV only cases. HIV n = 1283 and HIV/Latent TB n = 68. 
 
57 (83.8%) of 68 latent TB individuals had birth-place information in the database, of whom, 8 
(14.0%) were born in Canada (non-Aboriginals), 31 (54.4%) were born in Africa, 5 (8.8%) were 
born in Caribbean or Latin America, 4 (5.9%) were born in Asia or Pacific Regions, 3 (4.4%) in 
Europe or Central Asia and 2 (2.9%) in South Asia.  
  
43 (63.2%) of latent TB individuals born outside of Canada provided information on the length 
of stay in Canada, of whom 18 (26.5%) lived for less than 5 years and 25 (36.8%) lived for more 




In terms of HIV transmission risk, the highest proportion were of people from HIV endemic 
countries (32; 47.1%), 17 (25.0%) were MSM, 5 (7.4%) were heterosexual, 2 (2.9%) were IDUs 
and 12 (17.6%) were categorized under the others category.  
 
 
Of the 68 latent TB, 63 (92.6%) had a record of Mantoux skin test in the database and were 
identified as latent TB cases based on the Mantoux results. Five (7.4%) had no previous record 









8.4 Bivariate and Multivariate Analysis8 
Proportions of cases with outcome variable (active TB, latent TB, Mantoux test record) and HIV, 
were compared with proportions of HIV only. Bivariate analyses were performed to calculate the 
unadjusted odds ratio. Multivariate analyses were performed to calculate the adjusted odds ratio. 
The final variables included in the multivariate analysis were sex, age, birthplace region, HIV 
transmission risk, follow-up duration, and smoking status. There was evidence of collinearity 
between the birthplace region and HIV transmission risk variable as individuals born in Africa 
(birthplace variable) and individuals from HIV endemic countries (HIV transmission risk 
variable) would have assessed the same cases. Results from models with and without the 
inclusion of HIV transmission variable are shown below. 
 
8.4.1 Factors associated with active TB  
Results of the logistic regression analysis that identifies factors associated with active TB and 
HIV are provided in table 8.4a (1) and 8.4a (2). Although there was no significant interaction 
among the variables, collinearity was found in the HIV transmission risk variable as one of its 
categories (HIV endemic country) in the variable had an overlap with one of the categories 
(Africa) of the birthplace region variable. Table 8.4a (1) shows results of bivariate and 
multivariate analysis including the HIV transmission risk variable whereas table 8.4a (2) shows 
results after excluding this variable.  
 
                                                
8 Multivariate analysis results computed in SPSS are shown in Appendix C. 
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Results indicate that females with HIV were 3.5 times (95% CI 2.2 – 5.7, p < 0.001) more likely 
to have active TB than males with HIV but when adjusted for age, birthplace region, HIV 
exposure, follow-up duration and smoking status, the risk was reduced to 1.2 times (95 % CI 0.6 
– 2.5, p = 0.56) and was not statistically significant.  
 
The age analysis showed that before adjusting, individuals with HIV aged 30 to 50 were 1.1 
times (95% CI 0.7 – 1.9, p = 0.601) and individuals with HIV aged greater than 50 were 1.5 
times (95% CI 0.6 – 3.5, p = 0.337) more likely to have TB than individuals aged less than 30. 
This risk, however, was not significant. After adjusting for sex, birthplace region, HIV exposure, 
follow-up duration and smoking status, a significant risk was found in individuals aged 50 and 
over as they were 3.7 times (95% CI 1.2 – 10.9, p = 0.01) more likely to have active TB.  
 
In terms of birthplace region, bivariate and multivariate analysis compared individuals who were 
born in Canada (non-aboriginals) with Aboriginal Canadians, individuals born in Africa, 
Caribbean and Latin America. Aboriginal Canadians had a slightly increased risk (OR 1.05 95% 
CI 0.2 – 4.8, p = 0.94) of having TB than non-Aboriginal Canadians but when adjusted for age, 
sex, HIV exposure, follow-up duration and smoking status, the risk of TB decreased (OR 0.7 
95% CI 0.1-3.5, p = 0.70). Both risks were statistically not significant.  
 
Individuals with HIV who were born in Africa were at a much higher risk as they were 17.2 
times (95% CI 8.4 – 34.6, p <0.001) more likely to have active TB than non-aboriginal 
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Canadians. After adjusting for age, sex, HIV exposure, follow-up duration and smoking status, 
the risk of TB decreased to 7.6 times (95% CI 1.9 – 39.1, p = 0.004) but was still statistically 
significant.  
 
Similarly, individuals with HIV who were born in Caribbean or Latin America were 3.1 times 
(95% CI 1.1 – 8.4, p = 0.02) more likely to have active TB than non-aboriginal Canadians. 
However, after adjusting for age, sex, HIV exposure, follow-up duration and smoking status, the 
risk of TB not only decreased to 2.2 times (95% CI 0.6 – 8.2, p = 0.2) but also was not 
significant.  
 
Individuals who were in the HIV endemic category of the HIV exposure variable were 14.6 
times (95% CI 7.3 – 29.2, p <0.001) more likely to have active TB than those in the MSM 
category. After adjusting for age, sex, birthplace region, follow-up duration and smoking status, 
the risk reduced to 3.2 times (95% CI 0.8 – 12.7, p = 0.09) and was not statistically significant.  
 
Individuals who were in the heterosexual category were 3.4 times (95% CI 1.3 – 8.7) more likely 
to have active TB than those in the MSM category. After adjusting for age, sex, birthplace 
region, follow-up duration and smoking status, the risk was slightly reduced to 3.0 times (95% 




Individuals who acquired HIV infection through IDU contact were 2.1 times (95% CI 0.7 – 6.1, 
p = 0.176) more likely to have active TB than those in the MSM category but this was not 
statistically significant. When adjusted for age, sex, birthplace region, follow-up duration and 
smoking status, the risk slightly increased to 2.2 times (95% CI 0.7 – 7.2, p = 0.171) and 
remained not significant.  
 
In terms of duration of follow up, individuals who were followed up in the study for more than 
12 months were 2.4 times (95% CI 1.3 – 4.4, p <0.01) more likely to have TB than individuals 
who were followed up for less than 12 months. After adjusting for age, sex, birthplace region, 
HIV exposure, and smoking status, the risk decreased to 1.5 times (95% CI 0.7 – 2.9, p = 0.26) 
and was not significant.  
 
Before adjusting for age, sex, birthplace region, and HIV exposure, individuals with HIV who 
never smoked had a higher chance (OR 2.6; 95% CI 1.4 – 4.8, p <0.05) of acquiring TB than 
individuals who smoked frequently, however, after adjusting, individuals who never smoked had 
less risk (OR 0.9; 95% CI 0.4 – 2.0, p < 0.85) than individuals who smoked but was not 
significant.  
 
After removing the HIV transmission variable from the multivariate analysis, significant factors 
associated with active TB were age and birthplace region. Individuals with HIV aged 50 and 
older were 4.3 times (95% CI 1.5 – 12.7, p = 0.006) more likely to have active TB than 
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individuals aged 30 and younger. Similarly, individuals born in Africa were 14 times (95% CI 
5.9 – 32.8, p < 0.0001) more likely to have active TB than those born in Canada. Individuals 
born in Caribbean & Latin America were also more likely to have active TB than those born in 
Canada (OR 3.3, 95% CI 1.1-9.3, p = 0.028). Results are shown in Table 8.4 a (2).  
  
 
                                Table 8.4.a(1) – Factors associated with active TB 
                                                                                                93  
Active TB Cases (n =76) Cases with TB/HIV Cases with HIV only Unadjusted 
OR 
95% CI p-value Adjusted 
OR 
95 % CI p-value 
 n % n %       
Sex           
Male 40 4.0 969 96.0 1   1   
Female 35 12.8 239 87.2 3.5 2.2-5.7 <0.001 1.2 0.6 – 2.5 0.56 
           
Age           
<30 20 5.2 364 94.8 1   1   
30-50 48 6.0 757 94.0 1.1 0.7-1.9 0.601 1.7 0.9 – 3.5 0.099 
>50 8 7.7 96 92.3 1.5 0.6-3.5 0.337 3.7 1.2 – 10.9 0.016 
           
Birthplace Region           
Canada (non-Aboriginals) 11 1.7 628 98.3 1   1   
Aboriginal Canadians 2 1.8 108 98.2 1.05 0.2 – 4.8 0.943 0.7 0.1  - 3.5 0.708 
Africa 39 23.2 129 76.8 17.2 8.6-34.6 <0.001 7.6 1.9 – 30.1 0.004 
Caribbean & Latin America 6 5.3 108 94.7 3.1 1.1-8.4 0.026 2.2 0.6 – 8.2 0.210 
Others 8 4.9 155 95.1 2.9 1.2-7.1 0.022 3.1 1.2 – 8.2 0.019 
           
HIV transmission mode           
MSM 11 1.6 673 98.4 1   1   
HIV Endemic 39 19.3 163 80.7 14.6 7.3 – 29.2 <0.0001 3.2 0.8-12.7 0.094 
IDU 5 3.3 146 96.7 2.1 0.7 – 6.1 0.176 2.2 0.7-7.2 0.171 
Heterosexual 8 5.4 141 94.6 3.4 1.3 – 8.7 0.009 3.0 1.0 – 8.9 0.039 
Others 13 12.1 94 87.9 8.4 3.6 – 19.4 <0.001 3.7 0.7 – 20.2 0.122 
           
Duration of Follow-up            
<12 months 13 3.1 409 96.9 1   1   
>12 months 57 7.1 746 92.9 2.4 1.3 – 4.4 0.005 1.5 0.7 – 2.9 0.262 
           
Smoking Status           
Smoke 15 3.4 422 96.6 1   1   
Never 38 8.5 410 91.5 2.6 1.4 - 4.8 0.002 0.9 0.43 – 2.0 0.856 





Table 8.4.a (2) – Factors associated with active TB (excluding HIV transmission variable) 
 
 
Active TB Cases (n =76) Cases with TB/HIV Cases with HIV only Unadjusted 
OR 
95% CI p-value Adjusted 
OR 
95 % CI p-value 
 n % n %       
Sex           
Male 40 4.0 969 96.0 1   1   
Female 35 12.8 239 87.2 3.5 2.2-5.7 <0.001 1.8 0.9-3.5 0.077 
           
Age           
<30 20 5.2 364 94.8 1   1   
30-50 48 6.0 757 94.0 1.1 0.7-1.9 0.601 1.7 0.9 – 3.5 0.094 
>50 8 7.7 96 92.3 1.5 0.6-3.5 0.337 4.3 1.5 – 12.7 0.006 
           
Birthplace Region           
Canada (non-Aboriginals) 11 1.7 628 98.3 1   1   
Aboriginal Canadians 2 1.8 108 98.2 1.05 0.2 – 4.8 0.943 0.9 0.1  - 4.2 0.708 
Africa 39 23.2 129 76.8 17.2 8.6-34.6 <0.001 14.0 5.9 - 32.8 0.0001 
Caribbean & Latin America 6 5.3 108 94.7 3.1 1.1-8.4 0.026 3.3 1.1 – 9.3 0.028 
Others 8 4.9 155 95.1 2.9 1.2-7.1 0.022 3.2 1.2 – 8.2 0.015 
           
Duration of Follow-up            
<12 months 13 3.1 409 96.9 1   1   
>12 months 57 7.1 746 92.9 2.4 1.3 – 4.4 0.005 1.5 0.7 – 2.9 0.262 
           
Smoking Status           
Smoke 15 3.4 422 96.6 1   1   
Never 38 8.5 410 91.5 2.6 1.4 - 4.8 0.002 0.9 0.43 – 2.0 0.856 
Former Smoker 8 3.8 201 96.2 1.1 0.4 – 2.6 0.8 0.8 0.30 – 2.0 0.649 
8.4.2 Factors associated with Latent TB  
Results of the logistic regression analysis that identifies factors associated with latent TB and 
HIV are provided in table 8.4b (1). Proportions of cases with latent TB and HIV were compared 
with proportions of cases with HIV only. Bivariate analysis was performed to calculate the 
unadjusted odds ratio. Multivariate analysis was performed to calculate the adjusted odds ratio.  
  
Females with HIV were 4.4 times (95% CI 2.7 - 7.3, p < 0.001) more likely to acquire latent TB 
than males. After adjusting for age, birthplace region, HIV exposure risk, follow-up duration, 
and smoking status, the risk of acquiring latent TB for females was 2.5 times (95% CI 1.0 – 6.02, 
p < 0.05) more than males.  
  
Individuals with HIV aged 30 to 50 years had similar risk (OR 0.8; 95% CI 0.4 - 1.4, p = 0.83) of 
being with latent TB than individuals aged 30 and less. After adjusting, the latent TB risk 
increased as the individuals aged 30 to 50 years were 1.2 times (95% CI 0.6 – 2.4, p = 0.57) 
more likely to be infected with latent TB than individuals aged 30 and less. Both risks were 
statistically not significant. Similarly, individuals with HIV aged 50 years and over had slightly 
increased risk (OR 1.2; 95% CI 0.4 – 1.4, p = 1.1) of acquiring latent TB than individuals aged 
30 and less. After adjusting for sex, birthplace region, HIV exposure risk, follow-up duration, 
and smoking status, the risk further increased to 1.9 times (95% CI 0.5 – 6.6, p = 0.33) but 




There were no Aboriginal Canadians found to be infected with latent TB in the database. 
Individuals with HIV who were born in Africa were 20.9 times (95% CI 9.4 – 46.5, p < 0.001) 
more likely to have latent TB than non-Aboriginal Canadians. After adjusting for age, sex, HIV 
exposure risk, follow-up duration, and smoking status, the risk dropped to 11. 9 times (95% CI 
2.4 – 58.1, p < 0.002) but remained statistically significant. Individuals with HIV who were born 
in Caribbean or Latin America were 4.2 times (95% CI 1.3 – 13.2, p < 0.05) more likely to have 
latent TB than non-Aboriginal Canadians. After adjusting, the risk dropped to 1.9 times (95% CI 
0.4 – 9.3, p < 0.40) and was statistically not significant.  
 
Individuals who were in the HIV endemic country category of the HIV transmission risk variable 
were 7.3 times (95% CI 4.0 – 13.6, p < 0.0001) more likely to have latent TB than those in the 
MSM category. After adjusting for age, sex,  birthplace region, follow-up duration, and smoking 
status, individuals who acquired HIV infection through HIV endemic country were less likely 
(OR 0.9; 95% CI 0.2 – 4.7, p = 0.98) to be infected with latent TB than those in the MSM 
category. There was no statistical significance difference in the risk between the two groups.  
 
Individuals who were in the heterosexual category were 1.3 times (95% CI 0.4 – 3.7, p = 0.5) 
more likely to have latent TB than those in the MSM category. After adjusting, individuals in the 
heterosexual category were less likely (OR 0.9; 95% CI 0.2 – 3.3, p = 0.89) to be infected with 
latent TB than those in the MSM category. The difference also however, was not statistically 




Individuals in the IDU contact category were less likely (OR 0.5; 95% CI 0.1 – 2.3, p = 0.39) to 
be infected with latent TB than those in the MSM category. The risk difference was not 
significant. The risk was not significant even after adjusting for age, sex, birthplace region, 
follow-up duration, and smoking status (OR 0.3; 95% CI 0.04 – 2.8, p = 0.32).  
 
In terms of duration of follow-up, participants who were followed up in the study for more than 
12 months provided more exposure in the database and were 2.1 times (95% CI 1.1 – 3.9, p < 
0.05) more likely to have latent TB than individuals who were followed up for less than 12 
months. After adjusting for age, sex, birthplace region, HIV exposure risk, and smoking status, 
the risk decreased to 1.7 times (95% CI 0.7 – 3.7, p = 0.18) but was not significant.  
 
Before adjusting for potential confounding factors, individuals with HIV who never smoked had 
a higher odds (OR 3.4; 95% CI 1.6 – 6.9, p < 0.01) of acquiring TB than individuals who 
smoked frequently, however, after adjusting for age, sex, birthplace region, HIV exposure risk, 
and follow-up duration, individuals who never smoked had less risk (OR 0.8; 95% CI 0.3 – 2.0, p 
< 0.75) than individuals who smoked but was not significant.  
 
After removing the HIV transmission variable from the multivariate analysis, significant factors 
associated with latent TB were sex and birthplace region. Females were 2.4 times more likely 
(95% CI 1.1 – 5.2, p = 0.017) to have latent TB than males. Individuals born in Africa were 12 
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times (95% CI 4.7 – 32.1, p < 0.0001) more likely to have latent TB than those born in Canada. 


















Table 8.4b (1) – Factors associated with latent TB 
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 Latent TB Cases (n = 68)  Cases with TB Cases without TB Unadjusted 
OR 
95% CI p-value Adjusted 
OR 
95 % CI p-value 
 n % n %       
Sex           
Male 32 3.2 977 96.8 1   1   
Female 35 12.8 239 87.2 4.4 2.7 – 7.3 <0.001 2.5 1.0 – 6.02 0.046 
           
Age           
<30 22 5.7 362 94.3 1   1   
30-50 39 4.8 766 95.2 0.8 0.4 – 1.4 0.838 1.2 0.6 – 2.4 0.575 
>50 7 6.7 97 93.3 1.2 0.4 – 2.8 1.187 1.9 0.5 – 6.5 0.328 
           
Birthplace Region           
Canada (non-Aboriginals) 8 1.3 631 98.7 1   1   
Aboriginals Canadians 0 0 110 100    - - - 
Africa 31 18.5 137 81.5 20.9 9.4 – 46.5 <0.001 11.9 2.4 – 58.1 0.002 
Caribbean & Latin America 5 4.4 109 95.6 4.2 1.3 – 13.2 <0.05 1.9 0.4 – 9.3 0.406 
Others 13 8.0 150 92.0 8.0 3.2 – 19.7 <0.001 4.9 2.1 – 15.1 0.001 
           
HIV Transmission           
MSM 17 2.5 667 97.5 1   1   
HIV Endemic 32 15.8 170 84.2 7.3 4.0 -13.6 <0.0001 0.9 0.2 – 4.7 0.98 
IDU 2 1.3 149 98.7 0.5 0.1 – 2.3 0.39 0.3 0.04 – 2.8 0.32 
Heterosexual 5 3.4 144 96.6 1.3 0.4 – 3.7 0.5 0.9 0.2 – 3.3 0.89 
Others 12 11.2 95 88.8 4.9 2.2 – 10.7 <0.001 1.9 0.3 – 11.3 0.47 
           
Duration of Follow-up            
<12 months 50 6.2 753 93.8 1   1   
>12 months 13 3.1 409 96.9 2.1 1.1 – 3.9 0.02 1.7 0.7 – 3.7 0.18 
           
Smoking Status           
Smoke 10 2.3 427 97.7 1   1   
Never 33 7.4 415 92.6 3.4 1.6 – 6.9 <0.01 0.8 0.3 – 2.06 0.75 





Table 8.4b (2) – Factors associated with latent TB (excluding HIV transmission variable) 
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 Latent TB Cases (n = 68)  Cases with TB Cases without TB Unadjusted 
OR 
95% CI p-value Adjusted 
OR 
95 % CI p-value 
 n % n %       
Sex           
Male 32 3.2 977 96.8 1   1   
Female 35 12.8 239 87.2 4.4 2.7 – 7.3 <0.001 2.4 1.1 – 5.2 0.017 
           
Age           
<30 22 5.7 362 94.3 1   1   
30-50 39 4.8 766 95.2 0.8 0.4 – 1.4 0.838 1.2 0.6 – 2.3 0.593 
>50 7 6.7 97 93.3 1.2 0.4 – 2.8 1.187 1.7 0.5 – 6.2 0.360 
           
Birthplace Region           
Canada (non-Aboriginals) 8 1.3 631 98.7 1   1   
Aboriginals Canadians 0 0 110 100    - - - 
Africa 31 18.5 137 81.5 20.9 9.4 – 46.5 <0.001 12.3 4.7 – 32.1 0.0001 
Caribbean & Latin America 5 4.4 109 95.6 4.2 1.3 – 13.2 <0.05 1.7 0.4 – 7.06 0.418 
Others 13 8.0 150 92.0 8.0 3.2 – 19.7 <0.001 5.4 2.0 – 14.1 0.001 
           
           
Duration of Follow-up            
<12 months 50 6.2 753 93.8 1   1   
>12 months 13 3.1 409 96.9 2.1 1.1 – 3.9 0.02 1.7 0.7 – 3.7 0.178 
           
Smoking Status           
Smoke 10 2.3 427 97.7 1   1   
Never 33 7.4 415 92.6 3.4 1.6 – 6.9 <0.01 0.9 0.4 – 2.1 0.661 
Former Smoker 8 3.8 201 96.2 1.7 0.6 – 4.3 0.27 1.2 0.4 – 3.37 0.668 
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8.4.3 Factors associated with having a Mantoux test in the OCS database        
Results of the logistic regression analysis that identifies factors associated with having a 
Mantoux test in the OCS database provided in table 8.4c. Proportions of cases with a record of 
Mantoux test were compared with proportions of cases without a record of Mantoux test. 
Bivariate analysis was performed to calculate the unadjusted odds ratio. Multivariate analysis 
was performed to calculate the adjusted odds ratio by adjusting for potential confounding 
variables. Such variables were sex, age, birthplace region, HIV exposure risk, follow-up 
duration, and smoking status. 
  
Females were less likely (OR 0.6; 95% CI 0.4 - 0.8, p < 0.001) to receive a Mantoux test than 
males. After adjusting for age, birthplace region, HIV exposure risk, follow-up duration, and 
smoking status, the risk remained significant (OR 0.5; 95% CI 0.3 - 0.8, p = 0.003). 
  
Age was not found to be a significant factor that is associated with receiving a Mantoux test. 
HIV infected persons aged 30 years and under did not have a significantly different proportion of 
Mantoux test records than persons aged 30 – 50 years and 50 and over years. The proportion 
remained insignificant after adjusting (<30 vs. 30-50, OR 0.8; 95% CI 0.6 - 1.1, p = 0.17) and 
(<30 vs. >50, OR 0.9; 95% CI 0.5 - 1.5, p = 0.75).  
  
Aboriginal Canadians were slightly less likely (OR 0.6 ; 95% CI 0.4 - 0.9, p = 0.03) to receive a 
Mantoux test than non-Aboriginal Canadians , however this difference became insignificant after 
adjusting for sex, age, HIV exposure risk, follow-up duration, and smoking status (OR 0.7, 95% 
102 
 
CI 0.4 - 1.1, p = 0.176). HIV infected persons born in Africa were less likely (OR 0.6; 95% CI, 
0.5 - 0.9, p = 0.02) to receive a Mantoux test than non-Aboriginal Canadians. This association 
remained significant after adjusting for sex, age, HIV exposure risk, follow-up duration, and 
smoking status (OR 0.4; 95% CI 0.1 - 0.8, p = 0.0019).  
  
In terms of HIV exposure risk, individuals in the heterosexual category were more likely (OR 
0.6; 95% CI 0.4 - 0.9, p = 0.04) to receive a Mantoux test than the individuals in the MSM 
category, but after adjusting for sex, age, birthplace region, follow-up duration, and smoking 
status, individuals in the HIV endemic countries category (OR 2.4; 95% CI 1.1 - 5.2, p = 0.02) 
and IDUs category (OR 1.8; 95% CI 1.1 - 2.8, p = 0.01) were the only groups associated with 
receiving a Mantoux test.  
  
Duration of follow up in the OCS study was not associated with receiving a Mantoux test (<12 
months vs. > 12 months, OR 1.1; 95% CI 0.8 - 1.4, p = 0.579). The results remained the same 
after adjusting for sex, age, birthplace region, HIV exposure, and smoking status (<12 months vs. 
> 12 months, OR 1.1; 95% CI 0.8 - 1.4, p = 0.733).  
 
After removing the HIV transmission variable from the multivariate analysis, significant factors 
associated with having a Mantoux test record in OCS were sex and smoking status. Females 
were less likely (OR 0.6; 95% CI 0.4 – 0.9, p < 0.01) to have a Mantoux test record in OCS than 
males. Individuals with HIV who were former smokers were more likely (OR 1.4; 95% CI 1.0 – 
2.1, p = 0.039) to have a Mantoux test record in OCS than individuals who currently smoked. 
Results are shown in Table 8.4 c (2).   
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Cases with a Mantoux Test 
record 
(n = 466) 






95% CI p-value Adjusted 
OR 
95 % CI p-value 
 n % n %       
Sex           
Male 338 33.5 671 66.5 1   1   
Female 126 46.0 148 54.0 0.6 0.4 – 0.8 <0.001 0.5 0.3 – 0.8 0.003 
           
Age           
<30 143 37.2 241 62.8 1   1   
30-50 289 35.9 516 64.1 1.05 0.8 – 1.3 0.654 0.8 0.6 – 1.1 0.275 
>50 34 32.7 70 67.3 1.2 0.7 – 1.9 0.393 0.9 0.5 – 1.5 0.756 
           
Birthplace Region           
Canada (non-Aboriginals) 212 33.2 427 66.8 1   1   
Aboriginals Canadians 48 43.6 62 56.4 0.6 0.4 – 0.9 0.03 0.7 0.4 – 1.1 0.176 
Africa 72 42.9 96 57.1 0.6 0.5 – 0.9 0.02 0.4 0.1 – 0.8 0.019 
Caribbean & Latin America 39 34.2 75 65.8 0.9 0.6 – 1.4 0.82 0.9 0.5 – 1.5 0.756 
Others 63 38.7 100 61.3 0.8 0.5 – 1.1 0.18 0.8 0.5 – 1.3 0.513 
           
HIV Transmission           
MSM 237 34.6 447 65.4 1   1   
HIV Endemic 79 39.1 123 60.9 0.8 0.6 – 1.1 0.245 2.4 1.1 – 5.2 0.028 
IDU 47 31.1 104 68.9 1.1 0.8 – 1.7 0.408 1.8 1.1 – 2.8 0.010 
Heterosexual 65 43.6 84 56.4 0.6 0.4 – 0.9 0.040 1.1 0.6 – 1.7 0.779 
Others 38 35.5 69 64.5 0.9 0.6 – 1.4 0.861 0.8 0.3 – 2.2 0.714 
           
Duration of Follow-up            
<12 months 156 37.0 266 63.0 1   1   
>12 months 284 35.4 519 64.6 1.1 0.8- 1.4 0.579 1.1 0.8 – 1.4 0.733 
Smoking Status           
Smoke 171 39.1 266 60.9 1   1   
Never 159 35.5 289 64.5 1.1 0.8 – 1.5  0.263 1.4 1.0 – 1.9 0.036 
Former Smoker 62 29.7 147 70.3 1.5 1.0 – 2.1 0.019 1.6 1.1 – 2.3 0.013 
 
Figure 8.4c (2) Factors associated with having a Mantoux test record in the OCS database (excluding HIV transmission variable) 
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Cases with a Mantoux Test 
record 
(n = 466) 
Cases with Mantoux 
test 




95% CI p-value Adjusted 
OR 
95 % CI p-value 
 n % n %       
Sex           
Male 338 33.5 671 66.5 1   1   
Female 126 46.0 148 54.0 0.6 0.4 – 0.8 <0.001 0.6 0.4 – 0.9 0.01 
           
Age           
<30 143 37.2 241 62.8 1   1   
30-50 289 35.9 516 64.1 1.05 0.8 – 1.3 0.654 0.8 0.6 – 1.1 0.421 
>50 34 32.7 70 67.3 1.2 0.7 – 1.9 0.393 0.9 0.5 – 1.6 0.880 
           
Birthplace Region           
Canada (non-Aboriginals) 212 33.2 427 66.8 1   1   
Aboriginals Canadians 48 43.6 62 56.4 0.6 0.4 – 0.9 0.03 0.8 0.5 – 1.2 0.328 
Africa 72 42.9 96 57.1 0.6 0.5 – 0.9 0.02 0.7 0.1 – 0.8 0.256 
Caribbean & Latin America 39 34.2 75 65.8 0.9 0.6 – 1.4 0.82 1.2 0.7 – 1.9 0.450 
Others 63 38.7 100 61.3 0.8 0.5 – 1.1 0.18 0.8 0.5 – 1.2 0.405 
           
Duration of Follow-up            
<12 months 156 37.0 266 63.0 1   1   
>12 months 284 35.4 519 64.6 1.1 0.8- 1.4 0.579 1.1 0.7 – 1.4 0.758 
           
Smoking Status           
Smoke 171 39.1 266 60.9 1   1   
Never 159 35.5 289 64.5 1.1 0.8 – 1.5  0.263 1.2 0.9 – 1.7 0.128 
Former Smoker 62 29.7 147 70.3 1.5 1.0 – 2.1 0.019 1.5 1.0 – 2.1 0.039 
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CHAPTER 9 DISCUSSION         
9.1 Active TB among individuals with HIV 
To our knowledge, the present study is the only study that estimates active TB and latent TB 
rates in people infected with HIV in Ontario. While there has been no national or provincial 
surveillance system that tracks TB cases in people with HIV, several Canadian studies with 
varied methodology have estimated the burden of TB and HIV in the past (84-88).  
 
Results in our study have estimated active TB rate to be 5.9% among the HIV infected persons in 
the OCS. Brassard and Remis (1999) reported that 5.2% had active TB in 4684 AIDS-infected 
people in Quebec (86). Similarly, in another study by Geduld and Archibald (2005), 5.6% of all 
the AIDS reported to PHAC during 1994 to 2003 were co-infected with active TB cases (84). In 
contrast, studies that examined TB-HIV co-infection by estimating HIV infection among active 
TB cases, have reported much higher co-infection rates. Studies by Blenkush et al (1996) (85) 
and Kim et al (2008) (103) have reported the co-infection rate to be as high as 13.8% and 24.5%, 
respectively. Although, the TB rate reported by Geduld and Archibald (84) and Brassard and 
Remis (86) is similar to the rate of this study, they reported the TB rate only among the AIDS 
cases.  
 
Our TB-HIV cases are likely to underestimate the true numbers of HIV-TB cases in the OCS 
cohort. While the OCS cohort represents a diverse group of people living with HIV in Ontario, it 
106 
 
does not capture all the HIV infections.  One reason could be because it does not gather data 
from all the HIV clinics in Ontario. Further, groups such as Infants and temporary immigrants 
who may not permanently reside in Ontario are not likely to participate in OCS.  
 
Secondly, it can be seen from figure 8.1a that majority of the participants in the OCS are 
recruited during 2 to 5 years (37%) or even after 5 years (32.6%) of their HIV diagnosis. This 
increases the possibility that many individuals who are diagnosed with HIV between the years of 
2007 and 2010 with active TB would not have been recruited for the OCS until later in 2012 or 
2013.  
 
9.1.1 MDR-TB among individuals with HIV 
There were no MDR-TB cases found in the OCS database. The attempt to identify drug resistant 
TB cases was based on TB medication history and duration of treatment. However, none of the 
cases matched the criteria for having MDR-TB. Although HIV infection is associated with 
MDR-TB in institutional settings such as hospitals and prisons, it is unclear if there is any 
association between MDR-TB and HIV in a community setting (104). Several studies have 
shown HIV infection to be highly correlated with MDR-TB (104-106). However, the association 
could be confounded by shared risk factors such as injection drug use, imprisonment, 




There are several reasons why MDR-TB cases could not have been identified or were not present 
in the database. Firstly, any OCS participants infected with MDR-TB would most likely be 
seeking treatment under the Directs Observed Therapy Short-Course (DOTS) program by Public 
Health, which means that medication history may not have been captured in the OCS. Secondly, 
the proportion of MDR-TB cases in Canada is much lower than the global average estimated by 
WHO (1.1% vs. 4.8%) (107). In the period of 10 years from 1998 to 2008, only 181 cases have 
been classified as MDR-TB (107). Thirdly, MDR-TB and HIV creates an extremely complex 
clinical scenario, which may lead to severe illness or even death. A study in Peru explored that 
more than 50% of HIV-infected MDR-TB patients died within two months of diagnosis (108). 
Other studies with longer follow up had a mortality rate of 72 to 89% (109). A UK study 
estimated that immune-compromised MDR-TB patients are nine times more likely to die than 
those non immune-compromised with MDR-TB (110). Due to the severity of the illness and the 
nature of MDR-TB, any individual infected with HIV and MDR-TB could have been too ill to 
participate in the OCS study. Fourthly, access to Public Health drug resistant TB culture results 
in the OCS database would have confirmed the presence of MDR-TB cases, however they were 
not available at the time this study was conducted.  
 
9.2 Latent TB among individuals with HIV 
While there were no studies that reviewed the latent TB rates all across Ontario, several 
Canadian studies have measured the number of positive Mantoux test rates (positive Mantoux 
test constitutes as a latent TB case) and have shown the rates to range from 10.2% to 35.6% (111 
- 114). The estimated prevalence of latent TB in our current study varies from 5.3% to 11.3% 
depending on the methodology. The prevalence rate of 5.3% for latent TB is certainly questioned 
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as the latent TB/HIV rate was expected to be quite higher than the active TB rate (5.8%). 
Therefore, the prevalence rate of 11.3% appears closer to the true prevalence of latent TB. It is 
still likely that the latent TB cases were under estimated. Possible explanations in the 
underestimation of latent TB include poor completion rates9 of Mantoux test and lack of 
sensitivity of this test in people with HIV may be another reason why physicians may not always 
use this test.  Furthermore, limited data capture ability of medications used for treatment of latent 
TB could also account for low latent TB estimate.  Anti-TB medications are often provided by 
Public Health and may not always be captured in the patient’s records at the HIV clinic sites.  
 
Studies (115-116) have examined the usage of TB skin testing for the screening of NTM in 
children. They have found TB skin testing as a valuable first step in screening for NTM in 
children without a history of TB exposure or BCG vaccination. In the study by Farhat et al. has 
conducted an extensive literature review and meta-analysis to determine the effect of NTM 
infection and a positive TST reaction (116). The study found that false-positive TB skin tests due 
to NTM were very uncommon and were only important in populations with a low prevalence of 
TB infection (116). Since our data mostly consists on adults with a high risk of TB, we believe 
that a positive TB skin test is indicative of a TB infection and therefore believe NTM has not had 
an impact on the results of our study. 
 
                                                
9 Further explained in section 9.3 (second paragraph) on the next page 
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9.3 Mantoux test records in the OCS database 
Although it is recommended that all HIV individuals should be screened for TB at the time of 
their HIV diagnosis (117), results in our study only found 466 (36%) Mantoux test records 
among the 1293 individuals diagnosed with HIV. This proportion was surprisingly lower than 
expected as 54% of the HOOD10 participants had a TB skin test record (118). Several other 
studies have also estimated the proportion of patients screening with Mantoux test that range 
from 54% to 69% (119-121). Only one study reported a lower rate (29%) of patients screened for 
TB than the rate of our study (14).  
  
Such low numbers of Mantoux test records in the OCS database may be explained by several 
factors. TB screening is different from other screening, as it requires a second visit, following the 
initial visit for the Mantoux test to be administered, for the results to be read. Failure to return 
will result in an incomplete screening and may explain the low proportion of Mantoux test 
records found in the OCS database. Another reason why Mantoux test record proportion may not 
be as high as expected could be related to the sensitivity in people with HIV as mentioned earlier 
in section 9.3. Mantoux test is not very sensitive in people with HIV and therefore physicians 
may not have always used this test.  Consequently, a reliable blood test to detect latent TB may 
help to improve the completion rates of TB screening.  Further, low numbers of Mantoux test 
records in the OCS database could also be a data capture issue. Records of Mantoux tests 
administered by Public Health and not HIV clinics may not have been captured by the OCS.  
  
                                                
10 HOOD stands for HIV Ontario Observational Database  
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9.4 Factors associated with active TB 
1293 individuals were diagnosed with HIV during 2001 to 2009, of which 76 (5.8%) had active 
TB. Multivariate analysis showed that the variables associated with active TB were age and 
birthplace region.  
 
Age was associated with active TB as individuals in the cohort living with HIV who were older 
(>50 years) were more likely to have TB. This association was expected since TB is more 
prevalent among older people in industrialized countries due to the decrease in risk of TB 
infection over recent decades (86) as well as a general decline of immune system as one gets 
older.  
 
In terms of birthplace region, individuals from Africa were at a higher risk of having active TB 
than non-Aboriginals individuals born in Canada. It is well documented that foreign-born 
individuals are at a much higher risk of TB (8). Foreign-born made account for a large number of 
TB cases in Europe. In countries such as Norway, Sweden and UK, more than 50% of the TB 
cases in 2003 were represented by foreign-born (122). The result of this study is consistent with 
other studies that have identified birthplace region to be a key risk factor that is associated with 
active TB and HIV (15, 86). 
 
The multivariate analysis did not find Aboriginal Canadians to be at a higher risk of having 
active TB. There was no significant difference between the proportion of non-Aboriginal 
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Canadians and Aboriginal Canadians in terms of having active TB (1.7% vs. 1.8%).  This was 
not expected as often Aboriginal Canadians are at a higher risk of having active TB. While 
Aboriginal Canadians continue to be over-represented in the HIV endemic, only a minority of 
individuals in the OCS reported themselves as Aboriginals (97). Aboriginal Canadians living on 
reserve may not visit the HIV clinics linked with OHTN as Health Canada is responsible for 
providing them with health services. Although living and working conditions are associated with 
high risk of TB transmission (123), many of the Aboriginal Canadians may be living in cities 
instead. Aboriginal Canadians living in cities may have a different socio-demographic profile 
than those living on reserves and thus could be the reason why our analysis did not show this 
group to be associated with having TB.  
 
Although, the sex variable was not associated with active TB, the proportion of women with 
active TB was higher than men with active TB. Results showed that 12.8% of women in the 
group had active TB whereas only 4% of men had active TB. This pattern was also found in 
another Canadian study where 13% of HIV infected women had TB whereas only 4% of men 
with HIV had TB (86). Overrepresentation of women in active TB cases could be explained by 
the fact that most female participants in the OCS come from HIV endemic countries where TB is 
also prevalent.  
 
9.5 Factors associated with latent TB 
Factors associated with having latent TB and HIV were also identified using bivariate and 
multivariate analysis. In the bivariate analysis, sex, birthplace region, HIV exposure category, 
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duration of follow up and smoking status were found to be associated with having a latent TB 
diagnosis. In the multivariate analysis, factors associated with having latent TB were sex and 
birthplace region as only females and people born in Africa were at an increased risk of having 
latent TB.  
 
9.6 Factors associated with having a Mantoux test record in the OCS database 
Factors associated with having a Mantoux test record in OCS were sex and smoking status. 
Females were slightly less likely to have a Mantoux test record in OCS than males. It is unclear 
whether this is related to the gender and screening practices among clinicians, or it is related to 
the type of data present in OCS. Majority of the females are foreign born in the study and may 
have had a TB test performed prior to coming to Canada. Since OCS does not collect data from 
immigration records, such individuals would not have a record of Mantoux test in OCS. 
 
In terms of smoking status, cigarette smoking in individuals with latent TB increase the risk of 
development of active TB. Therefore, it was expected that individuals who are current or former 
smokers would have more likely to have a Mantoux test record in OCS. However, multivariate 
analysis showed that only former smokers were marginally more likely to have a Mantoux test 
record in OCS than current smokers. As mentioned in section 3.5, smoking is more likely to be 





Although the data in OCS was initially composed mainly of gay men, it nevertheless was a 
diverse cohort of individuals who were fairly representative of the HIV-infected population in 
Ontario. Although, we cannot be certain that we have found all the TB cases based on diagnosis, 
screening test records and medication history, we believe the majority of the TB cases were 
captured. Although HIV clinics are the primary centre for treatment of HIV of the OCS 
participants, it could be likely that cases were diagnosed and treated elsewhere (e.g. Public 
Health Ontario or Public Health Toronto) for active or latent TB without the knowledge of HIV 
clinics.  
 
It is acknowledged that the present study had many limitations relating to data capture. While 
several studies on HIV/TB have relied on national and surveillance data (84-86) – data that is 
mandatory to be reported by clinicians, our study has used passive reporting and observational 
data which is provided by the participants on voluntary basis. Such type of data might induce 
selection bias as only individuals with similar characteristics would be willing to participate in 
OCS after their diagnosis of HIV. For example, a person who is severely ill and have a low CD4 
count may not be able to enrol in the OCS study.  
 
Our study was also dependent on the specific data elements available in OCS that would help 
achieve the research objectives of this study. Although we were able to identify the TB cases 
based on diagnosis and medication history data, other data points such as chest X ray results and 
TB lab culture results would have provided further confirmatory results. As there was no 
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availability of chest X ray and lab culture results, the estimates for active TB, particularly MDR-
TB would likely to be underestimated. It is also likely that most of the Mantoux test records in 
OCS were not captured from all the sites. Further, many Mantoux skin test records, related to the 
TB outcomes appeared to be incomplete, which increased the possibility of underestimating 
latent TB cases.  
 
Future work should include further TB related studies using OCS data including bacterial culture 
and chest X rays should be conducted. The data elements gathered across all the HIV sites 
should also be consistent and future work should contain OHTN site-specific analysis. The 
collection of medication history could be made more comprehensive by including documented 
barriers to DOTS or reasons for non-adherence and tolerance of TB treatment. Also, medication 
history should be linked with Public Health central information system so TB medications 
administered by Public Health can also be captured in the OCS.   
 
TB remains a major problem in persons infected with HIV with rates disproportionally high 
among the foreign born population. To identify individuals with higher risk of having TB after 
HIV diagnosis, better screening tools to identify latent TB are needed.  Low rates of Mantoux 
skin testing present a missed opportunity for active TB prevention among individuals with HIV.  
The findings of this study support the recommendations made by the Canadian thoracic Society 
to screen all patients for TB at the time of person's HIV diagnosis (117).  In order to optimize the 
HIV/TB management, a much more comprehensive data collection system is required which 
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Appendix A  WHO Clinical Staging of HIV/AIDS for Adults and Adolescents 
Primary HIV Infection 
• Asymptomatic 
• Acute retroviral syndrome 
Clinical Stage 1 
• Asymptomatic 
• Persistent generalized lymphadenopathy 
Clinical Stage 2 
• Moderate unexplained weight loss (<10% of presumed or measured body weight) 
• Recurrent respiratory infections (sinusitis, tonsillitis, otitis media, and pharyngitis) 
• Herpes zoster 
• Angular cheilitis 
• Recurrent oral ulceration 
• Papular pruritic eruptions 
• Seborrheic dermatitis 
• Fungal nail infections 
Clinical Stage 3 
• Unexplained severe weight loss (>10% of presumed or measured body weight) 
• Unexplained chronic diarrhea for >1 month 
• Unexplained persistent fever for >1 month (>37.6ºC, intermittent or constant) 
• Persistent oral candidiasis (thrush) 
• Oral hairy leukoplakia 
• Pulmonary tuberculosis (current) 
• Severe presumed bacterial infections (e.g., pneumonia, empyema, pyomyositis, bone or 
joint infection, meningitis, bacteremia) 
• Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis 
• Unexplained anemia (hemoglobin <8 g/dL) 
• Neutropenia (neutrophils <500 cells/µL) 
• Chronic thrombocytopenia (platelets <50,000 cells/µL) 
Clinical Stage 4 
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• HIV wasting syndrome, as defined by the CDC  
• Pneumocystis pneumonia 
• Recurrent severe bacterial pneumonia 
• Chronic herpes simplex infection (orolabial, genital, or anorectal site for >1 month or 
visceral herpes at any site) 
• Esophageal candidiasis (or candidiasis of trachea, bronchi, or lungs) 
• Extrapulmonary tuberculosis 
• Kaposi sarcoma 
• Cytomegalovirus infection (retinitis or infection of other organs) 
• Central nervous system toxoplasmosis 
• HIV encephalopathy 
• Cryptococcosis, extrapulmonary (including meningitis) 
• Disseminated nontuberculosis mycobacteria infection 
• Progressive multifocal leukoencephalopathy 
• Candida of the trachea, bronchi, or lungs 
• Chronic cryptosporidiosis (with diarrhea) 
• Chronic isosporiasis 
• Disseminated mycosis (e.g., histoplasmosis, coccidioidomycosis, penicilliosis) 
• Recurrent nontyphoidal Salmonella bacteremia 
• Lymphoma (cerebral or B-cell non-Hodgkin) 
• Invasive cervical carcinoma 
• Atypical disseminated leishmaniasis 
• Symptomatic HIV-associated nephropathy 
• Symptomatic HIV-associated cardiomyopathy 
• Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis) 




Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Female 274 21.2 21.4 21.4 
Male 1009 78.0 78.6 100.0 
Total 1283 99.2 100.0  
Missing System 10 .8   
Total 1293 100.0   
 
 
1.2 Age Categories (1) 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 30 - 50 805 62.3 62.3 62.3 
> 50 104 8.0 8.0 70.3 
<29 384 29.7 29.7 100.0 
Total 1293 100.0 100.0  
 
 
1.2 Age Categories (2) 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 12-19 35 2.7 2.7 2.7 
20 - 24 114 8.8 8.8 11.5 
45 - 64 249 19.3 19.3 30.8 
65 and above 7 .5 .5 31.3 
25 - 44 888 68.7 68.7 100.0 









1.3 Canadian Born vs Foreign Born 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Canadian Born 749 57.9 62.7 62.7 
Foreign Born 445 34.4 37.3 100.0 
Total 1194 92.3 100.0  
Missing Missing 99 7.7   
Total 1293 100.0   
 
 
2.4a Birthplace Region 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Africa 168 13.0 14.1 14.1 
Caribbean and Latin 
America 
114 8.8 9.5 23.6 
Others 163 12.6 13.7 37.3 
Aboriginal Canadians 110 8.5 9.2 46.5 
Canada (non abrg) 639 49.4 53.5 100.0 
Total 1194 92.3 100.0  
Missing System 99 7.7   




1.6b Years in Canada 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Less than 5 Years 102 7.9 25.8 25.8 
More than 5 Years 294 22.7 74.2 100.0 
Total 396 30.6 100.0  
Missing System 897 69.4   
Total 1293 100.0   
 
 




Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid MSM 684 52.9 52.9 52.9 
MSM-IDU 57 4.4 4.4 57.3 
IDU 94 7.3 7.3 64.6 
Clotting factor 7 .5 .5 65.1 
Transfusion 8 .6 .6 65.7 
HIV-endemic 202 15.6 15.6 81.4 
Heterosexual transmission 149 11.5 11.5 92.9 
MTC Mother to child 
transmission 
2 .2 .2 93.0 
NIR Non-identified risk 90 7.0 7.0 100.0 
Total 1293 100.0 100.0  
 
 
1.7 Urban / Rural Categorization 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid ON-RURAL 50 3.9 4.4 4.4 
ON-URBAN 1086 84.0 95.6 100.0 
Total 1136 87.9 100.0  
Missing OUT OF PROVINCE 14 1.1   
INVALID/MISSING 143 11.1   
Total 157 12.1   

















2.16a CD4 at Registration 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid >500 466 36.0 37.7 37.7 
200-500 632 48.9 51.1 88.8 
<200 139 10.8 11.2 100.0 
Total 1237 95.7 100.0  
Missing System 56 4.3   







Appendix C – Multivariate Analysis 
Factors associated with active TB 
 
B S.E. Wald df Sig. Exp(B) 




sex(1) .210 .365 .332 1 .565 1.234 .603 2.523 
AgeatHIVdiagnosis_var1   6.096 2 .047    
AgeatHIVdiagnosis_var1(1) .570 .346 2.717 1 .099 1.769 .898 3.485 
AgeatHIVdiagnosis_var1(2) 1.320 .549 5.775 1 .016 3.745 1.276 10.995 
Birth_Region   13.462 4 .009    
Birth_Region(1) 2.029 .703 8.337 1 .004 7.605 1.919 30.140 
Birth_Region(2) .823 .658 1.563 1 .211 2.277 .627 8.268 
Birth_Region(3) 1.148 .491 5.463 1 .019 3.152 1.204 8.255 
Birth_Region(4) -.299 .800 .140 1 .708 .741 .154 3.559 
HIVRisk_Var3   6.061 4 .195    
HIVRisk_Var3(1) 1.174 .700 2.812 1 .094 3.235 .820 12.758 
HIVRisk_Var3(2) .815 .596 1.870 1 .171 2.259 .702 7.265 
HIVRisk_Var3(3) 1.122 .543 4.275 1 .039 3.071 1.060 8.895 
HIVRisk_Var3(4) 1.327 .857 2.396 1 .122 3.768 .703 20.208 
Followup_Duration_car6(1) .395 .352 1.260 1 .262 1.485 .745 2.961 
CigaretteHistory_Var2   .209 2 .901    
CigaretteHistory_Var2(1) -.071 .391 .033 1 .856 .931 .433 2.004 
CigaretteHistory_Var2(2) -.223 .491 .207 1 .649 .800 .306 2.094 
Constant -5.117 .575 79.052 1 .000 .006   










Factors associated with Latent TB 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Step 1a sex(1) .905 .454 3.964 1 .046 2.471 1.014 6.021 
AgeatHIVdiagnosis_var1   .997 2 .608    
AgeatHIVdiagnosis_var1(1) .196 .350 .315 1 .575 1.217 .613 2.417 
AgeatHIVdiagnosis_var1(2) .631 .645 .957 1 .328 1.880 .531 6.657 
Birth_Region   18.478 4 .001    
Birth_Region(1) 2.469 .813 9.231 1 .002 11.815 2.402 58.109 
Birth_Region(2) .517 .801 .418 1 .518 1.678 .349 8.057 
Birth_Region(3) 1.602 .495 10.451 1 .001 4.962 1.879 13.102 
Birth_Region(4) -16.839 3833.309 .000 1 .996 .000 .000 . 
 MSM   1.687 4 .793    
HIV Endemic -.016 .806 .000 1 .984 .984 .203 4.772 
IDU -1.057 1.080 .958 1 .328 .347 .042 2.884 
Heterosexual -.090 .664 .018 1 .893 .914 .249 3.356 
Other .651 .908 .513 1 .474 1.917 .323 11.376 
Followup_Duration_car6(1) .527 .398 1.750 1 .186 1.694 .776 3.696 
CigaretteHistory_Var2   .502 2 .778    
CigaretteHistory_Var2(1) -.169 .437 .149 1 .700 .845 .359 1.989 
CigaretteHistory_Var2(2) .151 .519 .085 1 .771 1.163 .421 3.215 
Constant -4.813 .605 63.350 1 .000 .008   










Factors associated with receiving a Mantoux test 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Step 1a sex(1) -.653 .222 8.675 1 .003 .520 .337 .804 
AgeatHIVdiagnosis_var1   1.206 2 .547    
AgeatHIVdiagnosis_var1(1) -.165 .151 1.192 1 .275 .848 .630 1.141 
AgeatHIVdiagnosis_var1(2) -.084 .271 .097 1 .756 .919 .540 1.564 
Birth_Region   8.261 4 .082    
Birth_Region(1) -.925 .395 5.499 1 .019 .396 .183 .859 
Birth_Region(2) -.086 .276 .097 1 .756 .918 .534 1.577 
Birth_Region(3) -.132 .201 .429 1 .513 .877 .591 1.300 
Birth_Region(4) -.312 .231 1.835 1 .176 .732 .466 1.150 
HIVRisk_Var3   11.094 4 .026    
HIVRisk_Var3(1) .879 .401 4.799 1 .028 2.409 1.097 5.291 
HIVRisk_Var3(2) .586 .228 6.584 1 .010 1.797 1.148 2.811 
HIVRisk_Var3(3) .068 .243 .078 1 .779 1.070 .665 1.724 
HIVRisk_Var3(4) -.184 .503 .134 1 .714 .832 .310 2.230 
Followup_Duration_car6(1) .048 .139 .117 1 .733 1.049 .798 1.377 
CigaretteHistory_Var2   7.567 2 .023    
CigaretteHistory_Var2(1) .339 .162 4.379 1 .036 1.404 1.022 1.929 
CigaretteHistory_Var2(2) .477 .192 6.153 1 .013 1.611 1.105 2.349 
Constant .550 .188 8.581 1 .003 1.733   













Appendix D  Confidentiality Agreement 
 
       
CONFIDENTIALITY AGREEMENT 
BETWEEN: 
__________ARSALAN AFZAL____________ (“the Researcher”) 
- and - 
 
The Ontario HIV Treatment Network (“the OHTN”) 
 
WHEREAS the Researcher is employed by the OHTN or is engaged in research activities 
related to the OHTN Cohort Study using the Central Research Database of the OHTN or the HIV 
Ontario Observational Database for or under the auspices of the OHTN pursuant to a contractual 
or other relationship with the OHTN and has access to Confidential Information as defined 
herein; 
AND WHEREAS it is essential to the OHTN and its funding agencies that information provided 
to the OHTN for use in its research endeavours is kept strictly and absolutely confidential and in 
particular is handled in compliance with the Personal Health Information Protection Act of the 
Province of Ontario; 
AND WHEREAS the Researcher agreed, at the time he or she entered into employment with the 
OHTN or commenced his or her engagement to perform research or related activities for or 
under the auspices of the OHTN, to enter into an agreement with respect to confidential 
information and that he or she has received good and valuable consideration for entering into 
such agreement; 
NOW THEREFORE THE PARTIES HERETO AGREE: 
147 
 
1. For the purposes of this Agreement: 
(a) “Confidential Information” means information provided to the OHTN or 
gathered, known or used by or in the name of the OHTN in connection with its research 
endeavours or research activities performed under its auspices including but not limited 
to any data provided or gathered that contains Personal Health Information, De-
Identified Participant Information, data, programmes, codes, methods, techniques or 
processes, formula design, prototype, device, equipment or machine, Financial 
Information, Intellectual Property and Research and Development, but does not include 
any which is or becomes a matter of Public Knowledge; 
(b) “Financial Information” means information pertaining to the OHTN's funding, 
costs or operation. 
(c) “OHTN Cohort Study Research Policies" means the OHTN policies of the same 
name as it is from time to time; 
(d) “Public Knowledge" means information known generally in the scientific, 
research and health care communities, or which is easily obtained through lawful, non-
confidential sources such as publications. 
(e) “Research and Development” means information pertaining to any research, 
development investigation, study, analysis, experiment, or test carried on or proposed to 
be carried on by or under the auspices of the OHTN; 
(f) “De-identified Participant Information” means information under the 
custodianship of the OHTN about a living or deceased OHTN Cohort Study participant 
that has been stripped of all uniquely identifying data elements, such as name, address, 
health number or social insurance number. De-identified Participant Information can 
contain both demographic information, that is, information about an individual such as 
gender, ethnic origin age, level of education, etc., and health information, that is, 
information about an individual’s health care, such as conditions, treatments or 
medications. 
(g) “Personal Health Information” has the same meaning as that provided in the 
Personal Health Information Protection Act . Personal Health Information means 
identifying information about an individual in oral or recorded form, if the information, 
i) relates to the physical or mental health of the individual, including 
information that consists of the health history of the individual’s family, 
ii) relates to the providing of health care to the individual, including the 
identification of a person as a provider of health care to the individual, 
iii) is a plan of service within the meaning of the Long-Term Care Act, 1994 
for the individual, 




v) relates to the donation by the individual of any body part or bodily 
substance of the individual or is derived from the testing or examination 
of any such body part or bodily substance, 
vi) is the individual’s health number, or 
vii) identifies an individual’s substitute decision-maker. 
2. The researcher shall hold in confidence and keep confident all Confidential Information. 
3. The researcher will not use Confidential Information for any purpose other than that for 
which is was provided to him or her unless the researcher has the OHTN’s written 
authorization to do so. 
4. If applicable, the researcher will comply with the conditions and restrictions specified by 
the research ethics board approval submitted with the researcher’s application to use 
Confidential Information. 
5. The researcher will disclose or provide access to Confidential Information in a form in 
which the individual to whom it relates can be identified only to persons who have 
entered into Confidentiality Agreements with the OHTN and the researcher and shall be 
responsible to satisfy himself or herself in that regard.  Written confirmation from the 
Scientific and Executive Director that named individuals have executed such Agreements 
shall be deemed to compliance with this provision. 
6. The researcher will keep all Confidential Information in a physically secure location to 
which access is given only to the researcher and the persons mentioned above. 
7. The researcher will not contact any individual to whom Confidential Information relates, 
directly or indirectly, without the prior written authority of the OHTN. 
8. The researcher shall ensure that no Confidential Information will be used or disclosed in 
a form in which the individual to whom it relates can be identified without the written 
authority of the OHTN unless the use or disclosure is otherwise in compliance with this 
Agreement. 
9. The researcher shall notify the OHTN in writing immediately upon becoming aware that 
any of the conditions set out in this agreement have been breached. 
10. The researcher shall handle all Confidential Information in a manner consistent with the 
“OHTN Cohort Study Research Policies" unless the Policies are in some respect 
inconsistent with the terms herein, in which case the terms herein shall apply. 
 
ENTERED INTO this ___22nd ____ day of __October_______   2009___ 




Appendix E Data Scan Request Form 
	  
Ontario	  HIV	  Treatment	  Network	  (OHTN)	  
OHTN	  Cohort	  Study	  (OCS)	  	  
Data	  Scan	  Request	  Form	  
The	  OCS	  Data	  Scan	  is	  intended	  to	  determine	  whether	  there	  is	  a	  sufficient	  sample	  size	  to	  address	  
Research	  Question(s)	  of	  interest.	  





July	  21,	  2010	  
Date	  Required	   July	  26,	  2010	  
	  
	  







Email	  Address	   Clemon.George@uoit.ca	  
Phone	  Number	   905-­‐721-­‐8668x3659	  
	  
◊ P r o j e c t 	   T i t l e 	   	  
	  
◊ P r o j e c t 	   D e s c r i p t i o n 	   & 	   O b j e c t i v e ( s ) 	  




◊ I n c l u s i o n 	   & 	   E x c l u s i o n 	   C r i t e r i a 	  





◊ 	   D a t a 	   E l e m e n t s 	   R e q u i r e d 	   f o r 	   D a t a 	   S c a n  
HIV	  diagnosis	  date	  
Dates	  related	  to	  follow	  up	  in	  OCS	  (earliest	  seen	  date	  to	  last	  seen	  date,	  consent	  date)	  (not	  reported)	  
TB	  testing	  data	  from	  lab	  tests	  and	  adverse	  events	  datasets	  
The	  study	  seeks	  to:	  	  
1)	  Determine	  the	  prevalence	  of	  latent	  and	  active	  TB	  in	  the	  OHTN	  cohort	  study	  and	  the	  incidence	  of	  active	  TB;	  
2)	  Determine	  the	  prevalence	  and	  correlates	  of	  drug	  resistant	  TB;	  
3)	  Determine	  the	  occurrence	  of	  active	  TB	  co-­‐infection	  as	  a	  result	  of	  HAART	  induced	  immune	  reconstitution	  
syndrome.	  	  
4)	  Examine	  the	  association	  of	  active	  TB	  and	  previous	  negative	  Mantoux	  skin	  test;	  
5)	  Explore	  the	  factors	  associated	  with	  receiving	  a	  Mantoux	  test.	  
	  
Data	  scan:	  
Update	  earlier	  data	  scan	  numbers	  as	  part	  of	  developing	  Master’s	  student	  thesis	  proposal	  
Diagnosed	  as	  HIV+	  in	  2001	  or	  later	  
Diagnosed	  as	  HIV+	  earlier	  than	  2001	  	  
Incomplete	  testing	  data	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Site	  (not	  reported)	  
Source	  (not	  reported)	  
	  
◊ 	   D a t a 	   S u m m a r y 	   R e q u e s t e d 	  
PLEASE	  INDICATE	  CROSSTABS	  OR	  OTHER	  DESCRIPTIVE	  SUMMARIES	  OF	  KEY	  DATA	  ELEMENTS	  ONLY	  	  
	  
	  




-­‐ Current number in the OCS who were diagnosed as HIV+ in 2001 or later 
-­‐ Of these, how many have had a skin test for TB 
-­‐ Of these, how many have tested positive on their most recent TB skin test 
	  
Data	  will	  be	  reviewed	  by	  site	  and	  data	  source.	  	  However	  no	  summaries	  will	  be	  provided	  to	  the	  PI.	  	  We	  need	  to	  
understand	  if	  TB	  data	  is	  collected	  differently	  across	  sites	  and	  how	  this	  will	  affect	  thesis	  data	  analysis	  plan.	  	  
Recommendations	  may	  refine	  list	  of	  data	  elements	  required	  for	  data	  cut.	  	  
